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Abstract 
Chronic myeloid leukemia (CML) is a malignant hematologic disorder, which is fatal without a treatment. 
Oral tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of CML and transformed the 
disease to a chronic condition that can be treated at patient’s home. The common problem in the 
treatment of CML is patient’s poor adherence to TKIs. The regular, consistent use of TKIs is crucial to 
keep disease under control. For this reason and to obtain an optimal treatment outcome, adherence to 
TKIs is extremely important. 
 
The aim of the study was to assess reasons for poor adherence to TKI-medications in Finnish CML-
patients, including patient characteristics, treatment related factors, comorbidities and concomitant 
medications. In addition, patients’ experiences, beliefs, knowledge and perception about CML and its 
treatment were explored and how these could contribute to nonadherent behaviour. 
 
This study is part of the larger study, assessing adherence to TKI treatment among Finnish CML 
population. The data was obtained by using patient questionnaires and semi-structured theme-interview 
during patient meetings in 2012. Study population consisted of Finnish adult CML patients who had been 
on TKI -medication (imatinib, nilotinib or dasatinib) for more than six months prior to the study baseline. 
Patients’ adherence was measured using Morisky Medication Adherence 8-Item Scale (MMAS-8) and 
based on their score, patients were divided into three groups: high, medium and low adherence. Both 
quantitative and qualitative methods were used in data analysis. 
 
Study findings show that 21% (n=18) of the patients were low adherent and 23% (n=20) were high 
adherent to their treatment. Patient sociodemographic characteristics or experienced adverse drug 
reactions (ADRs) did not predict adherence, while more concomitant medications and comorbidities 
were associated with high adherence. However, ADRs had negative effect on the quality of life of 
several nonadherent patients. All nonadherent patients reported unintentional nonadherence and the 
most common reason was forgetting. Two-thirds of the patients (n=12) reported intentional 
nonadherence, which often was a result of experienced ADRs. The knowledge of CML and its treatment 
was poor among all patients while over half of the nonadherent patients (n=11) thought that they 
received enough information received. Overall, patients were very satisfied with care provided by the 
hospitals, physicians and other healthcare professionals. 
 
Managing TKI-treatment regimen is challenging for many patients and ADRs can have a negative impact 
on the quality of life. Healthcare professionals should regularly assess patient adherence and provide 
information and support for the patients to help them to succeed in medication management. Reasons 
for poor adherence are complex and have to be identified from each individual patient so that adherence 
can be improved.  
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Tiivistelmä 
Krooninen myelooinen leukemia (KML) on pahanlaatuinen verisairaus, joka ilman hoitoa johtaa 
kuolemaan. Suun kautta otettavat tyrosiinikinaasin estäjä (TKE) –lääkkeet ovat mullistaneet KML:n 
hoidon ja muuttaneet sen krooniseksi sairaudeksi, joka on mahdollista hoitaa potilaan omahoitona kotoa 
käsin. Sairauden hoidossa ongelmana on usein potilaan huono hoitoon sitoutuminen. TKE-lääkkeiden 
säännöllinen käyttö on erittäin tärkeää taudin kurissa pitämiseksi. Tästä syystä KML:n hoidossa on 
tärkeää huolehtia potilaan hyvästä hoitoon sitoutumisesta ja sen myötä lääkehoidon onnistumisesta. 
 
Tutkimuksen tavoitteena oli selvittää Suomalaisten KML-potilaiden TKE-lääkityksen huonoon hoitoon 
sitoutumiseen vaikuttavia tekijöitä, kuten sosiodemografinen tausta ja lääkehoitoon liittyvät tekijät sekä 
muut sairaudet ja lääkkeet.  Lisäksi tarkasteltiin huonosti hoitoon sitoutuneiden potilaiden kokemuksia, 
uskomuksia ja tietämystä lääkehoidosta ja sen toteuttamisesta, sekä kuinka nämä seikat saattavat 
vaikuttaa hoitoon sitoutumiseen. 
 
Tutkimus ja sen aineisto on osa laajempaa tutkimusta, joka käsittelee Suomalaisten KML-potilaiden 
hoitoon sitoutumista TKE-lääkkeisiin. Aineiston keruu toteutettiin kyselylomakkeilla ja puolistrukturoidulla 
teema-haastattelulla potilastapaamisissa vuonna 2012. Tutkimukseen otettiin mukaan 86 KML-potilasta 
jotka olivat käyttäneet TKI-lääke imatinibia (Glivec®), dasatinibia (Sprycel®) tai nilotinibia (Tasigna®) 
vähintään kuusi kuukautta. Potilaiden hoitoon sitoutumista mitattiin Morisky Medication Adherence 8-
item Scale (MMAS-8) kyselyllä, jonka perusteella potilaat jaettiin kolmeen eri ryhmään: hyvin, 
tyydyttävästi ja huonosti hoitoon sitoutuneet. Aineiston analyysissä käytettiin sekä kvantitatiivista että 
kvalitatiivista menetelmää. 
 
Potilaista 21% (n=18) olivat huonosti ja 23% (=20) hyvin hoitoon sitoutuneita. Sosiodemografiset tekijät 
eivät vaikuttaneet hoitoon sitoutumiseen. Hyvin hoitoon sitoutuneilla oli enemmän muita sairauksia ja 
lääkkeitä. Haittavaikutusten lukumäärä ei vaikuttanut hoitoon sitoutumiseen. Haittavaikutukset vaikuttivat 
kuitenkin negatiivisesti monien huonosti hoitoon sitoutuneiden elämänlaatuun. Kaikilla huonosti hoitoon 
sitoutuneilla  esiintyi tahatonta hoitoon sitoutumattomuutta, johon yleisin syy oli unohtaminen. Lisäksi yli 
kahdella kolmasosalla esiintyi tahallista hoitoon sitoutumattomuutta joka oli usein seurausta 
haittavaikutuksista. Kaikkien huonosti hoitoon sitoutuneiden potilaiden tietämys KML:stä ja TKE-
lääkkeestä oli heikkoa, vaikka usean (n=11) mielestä saatu informatio koettiin riittäväksi. Potilaat olivat 
erittäin tyytyväisiä saamaansa hoitoon sekä hoitohenkilökuntaan. 
 
KML:n omahoito on monille potilaille haasteellista ja aiheuttaa haittavaikutuksia, jotka voivat heikentää 
elämänlaatua. Hoitoonsitoutumista tulisi säännöllisesti arvioida ja hoitohenkilökunnan tulisi tukea ja 
informoida potilasta, sekä miettiä yhdessä keinoja omahoidon onnistumiseen. Huonoon hoitoon 
sitoutumiseen vaikuttavat tekijät tulisi tunnistaa yksilöllisesti jokaisen potilaan kohdalla, jotta hoitoon 
sitoutumista voitaisiin parhaiten edistää. 
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1 INTRODUCTION 
 
Anticancer therapy has historically been considered more as parental chemotherapy 
while medications that patients can administer orally have been less common form of 
therapy (Ruddy et al. 2009). However, a number of available oral anticancer 
medications has increased significantly in recent years (Ruddy et al. 2009; Verbrugghe 
et al. 2013). The majority of patients prefer to take their medication in the form of 
tablets instead of injection (Fallowfield et al. 2006; Verbrugghe et al. 2013). Oral 
administration is more convenient, can be taken at patients’ home, provides flexibility 
for the patients and improves the quality of life (Partridge et al. 2002; Fallowfield et al. 
2006; Verbrugghe et al. 2013). 
 
Because of the lack of effective treatment, chronic myeloid leukemia (CML) used to be 
inevitable fatal illness (Goldman and Melo, 2003). Imatinib, a tyrosine kinase inhibitor 
(TKI), was brought to the market in 2001 and caused a major change in the treatment of 
CML (Cohen et al. 2002; Baccarani et al. 2006). Orally administered imatinib can 
prevent illness from progressing to the advanced phases. If taken as prescribed, the 
patients with imatinib can achieve a good molecular response and long progression-free 
survival time (Druker 2008; Marin et al. 2010).  
 
Medication that is administered orally allows patients to be in charge of managing their 
treatment (Verbrugghe et al. 2013). The convenience of taking medications at home 
increases patients’ responsibility to manage their treatment and to take their medication 
as prescribed. Taking a daily medication as prescribed can be a challenging 
commitment to many patients with a chronic disease. Yet, patients’ adherence to the 
medication is a key factor in the treatment outcome (Noens et al. 2009). Because of the 
serious nature of the disease, it is often assumed that cancer patients are motivated to 
their oral cancer therapy (Partridge et al. 2002). However, adherence to oral anticancer 
medications has been reported ranging from 16% to fully adherent 100% (Ruddy et al. 
2009) and overadherence up to 120% when patients are taking more than the prescribed 
dose (Timmers et al. 2014). According to several studies, non-adherence is also 
common within CML patients (Noens et al. 2009; Marin et al. 2010). 
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Adherence within CML patients is essential for an optimal clinical outcome but it also 
has an impact on an economic outcome (Darkow et al. 2007). Nonadherence to the 
treatment can result in a poor clinical outcome and can affect patient’s quality of life 
and health care costs (The World Health Organization 2003). Several international 
studies have studied the reasons for the poor adherence among CML patients (Noens et 
al. 2009; Marin et al. 2010; Eliasson et al. 2011). Such study has not been done in 
Finnish CML population before.  To improve medication-taking behaviour and 
adherence among Finnish CML patients, it would be important to understand the 
underlying reasons for poor adherence.  
 
 
2 CANCER AS A DISEASE 
 
Cancer affects tens of millions of people worldwide and is one of the leading causes of 
death worldwide (Ma & Yu 2006; International Agency for Research on Cancer 2012a). 
According to GLOBOCAN Database, there were 32.6 million people living with cancer 
and 8.2 million deaths caused by cancer in 2012 (International Agency for Research on 
Cancer 2012a). It has been estimated that the number of all new leukemia cases in the 
world was approximately 352 000 in 2012 (International Agency for Research on 
Cancer 2012b) of which CML accounts for approximately 15% (Jabbour and Kantarjian 
2016). Based on this, the number of new CML cases in the world in 2012 was 
approximately 53 000. 
 
Cancer is the second most common cause of deaths in Finland after cardiovascular 
diseases (Official Statistics of Finland (OSF), 2014). In 2014, there were over 32 000 
new cancer cases and 12 000 cancer deaths in Finland (Finnish Cancer Registry 2016). 
The number of new cases of CML per year in Finland in 2010-2014 was 51 and number 
of deaths per year was 21 (Association of the Nordic Cancer Registries 2016). It has 
been estimated that one third of Finns will get cancer during their lifetime (Pukkila et al. 
2009). 
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A prognosis within the cancer patients is getting better as more effective treatment 
options are developed (Pukkala et al. 2011). New better therapies have significant effect 
on the survival rates of the cancer patients, such as patients with CML (Pukkala et al. 
2011; Baccarani et al. 2014).  
 
 
3 CHRONIC MYELOID LEUKEMIA 
 
3.1 Characteristics and pathophysiology 
 
Chronic myeloid leukemia (CML) is a disorder that originates in hematopoietic stem 
cells, which start to reproduce uncontrollably resulting in the excess amount of myeloid 
cells (Sawyers 1999; Druker 2008). These cells differentiate and function normally. As 
the disease transforms to the more advanced phases, the myeloid cells loses their ability 
to differentiate (Druker et al. 2001). Eventually follows the fatal acute leukemia, known 
as blast crisis, when abnormal myeloid or lymphoid blast cells start to accumulate 
rapidly (Calabretta and Perrotti, 2004; Druker 2008). Without a treatment, the disease 
will progress from a chronic phase through an accelerated phase (AP) to fatal acute 
leukemia, usually within four to six years (Druker 2008).  
 
The molecular pathogenesis of CML is associated with a Philadelphia (Ph) 
chromosome, a rearrangement of two chromosomes that results in the formation of a 
shortened chromosome 22 (Druker 2008). It is formed by a reciprocal translocation 
between parts of chromosomes 9 and 22 and carries a BCR-ABL fusion gene that has 
tyrosine kinase activity (Figure 1). The elevated activity of BCR-ABL tyrosine kinase 
results in increasing numbers of myeloid cells and genetic instability, which can lead to 
disease transformation (Druker 2008). The mechanism that leads to the formation of the 
Ph chromosome is unknown (Goldman and Melo 2003). The Ph chromosome is found 
in 95 % of the patients with CML (Sawyers 1999). 
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Figure 1. Reciprocal translocation between the long arms of chromosomes 9 and 22 
forms the Philadelphia (Ph) chromosome containing BCR-ABL fusion gene (Druker 
2008). 
 
Most CML patients are diagnosed during a chronic phase (Druker 2008). CML is 
usually found during routine physical examination or blood test and approximately 50% 
of the patients are asymptomatic at the time of diagnosis (Jabbour and Kantarjian 2016). 
When symptoms are present, patients may experience fatigue, malaise, weight loss, 
easy satiety and abdominal pain and fullness. These are the common signs and 
symptoms during the chronic phase of CML, resulting from anemia and splenomegaly. 
Diagnosis is based on the detection of the Philadelphia (Ph) chromosome abnormality 
or the Ph-related molecular BCR-ABL abnormalities (Jabbour and Kantarjian 2016). 
 
3.2 Epidemiology 
 
CML is a rare disease and accounts 0.1 to 0.2% of all cancers and about 15% of all 
leukemia (Hehlmann et al. 2007; Association of the Nordic Cancer Registries 2016; 
Jabbour and Kantarjian 2016). An incidence rates vary from 1 to 2 cases per 100 000 
people per year (Hehlmann et al. 2007). CML can occur at any age but is most 
frequently diagnosed between the ages of 40 and 70 years (Koskela et al. 2012). It is 
more common in men than in women (Hehlmann et al. 2007). Based on a French 
epidemiological study, an annual prevalence rate has increased from 5.8 in 1998 to 10.4 
in 2007, indicating that the use of tyrosine kinase inhibitor (TKI) imatinib has a positive 
5 
 
influence on the survival and life expectancy of patients with CML (Rohrbacher & 
Hasford 2009).  
 
In Finland, every year 50-60 people are diagnosed with CML (Koskela et al. 2012). 
According to the Association of the Nordic Cancer Registries, the prevalence of CML 
in Finland at the end of 2014 was 260 males and 204 females, prevalence per 100 000 
was 9 and 7; and number of deaths per year (2010-2014) 14 and 7, respectively 
(Association of the Nordic Cancer Registries 2016). The prevalence of CML in Finland 
can be also estimated based on the reimbursement records of the Social Insurance 
Institution of Finland (KELA). In Finland, TKIs imatinib, dasatinib and nilotinib are 
fully reimbursed by KELA for patients diagnosed with CML. At the end of 2015 there 
were 521 CML patients on TKIs of which 360 received imatinib, 71 dasatinib and 90 
nilotinib (Unpublished information from KELA, 2016; Kelasto 2015). The 
reimbursement costs for TKIs in CML patients were € 15.1 million in 2015 (Kelasto, 
2015). Reimbursements per prescription were  € 6957 for imatinib, € 8329 for dasatinib 
and € 7436 for nilotinib. 
 
 
4 THE TREATMENT OF CML 
 
The prognosis of CML has changed from a fatal disease to a chronic disorder that can 
be managed with a lifelong oral medication. The better understanding about the 
molecular pathogenesis of CML has made it possible to develop molecularly targeted 
therapies. (Baccarani et al. 2009; Jabbour et Kantarjian 2016). Imatinib was the first 
oral medication designed to selectively inhibit the BCR-ABL tyrosine kinase (Druker et 
al. 2008). After imatinib, three second-generation TKIs dasatinib, nilotinib and 
bosutinib and one third-generation TKI, ponatinib, have been developed (Kantarjian et 
al. 2010: Saglio et al. 2010, Jabbour et al. 2015). 
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4.1 The treatment goals  
 
The treatment goals of CML have been changed from palliative care to the prolongation 
of survival and to cure for patients eligible to allogeneic stem cell transplantation 
(Hehlmann et al. 2005). TKIs have started a new era in the treatment of CML, which 
has resulted that the treatment goals have turned to be more ambitious (Baccarani et al. 
2014). Current treatment goals include preventing CML to progress to the advanced 
phases and avoiding complications and deaths related to the TKI treatment. Third goal 
for patients is to have the quality of life and a length of survival equivalent to the person 
without CML. 
 
Molecular monitoring provides important prognostic information, as the response to 
TKIs is the most important prognostic factor (Baccarani et al 2013; Cross et al. 2015). 
The goals of TKI treatment have changed since imatinib became available, because of 
the progress in technology, standardization in molecular monitoring and bringing the 
second generation TKIs to the market (Baccarani et al. 2013 and 2014). Definitions of 
hematologic, cytogenetic and molecular responses are used to indicate a treatment 
outcome and are shown on Table 1 (Baccarini et al. 2014). A hematologic response 
refers to blood counts returning to normal values, a cytogenetic response to the 
disappearance of the Ph-chromosome and a molecular response to reduction in BCR-
ABL1 gene expression (Mahon and Etienne 2013). A major molecular response (MMR) 
equals a 3-log reduction in BCR-ABL1 transcript levels from a baseline (BCR-ABL1 ≤ 
0.1%). Sometimes the definition of a complete molecular response (CMR) is used, 
referring to 4.5-log reduction in BCR-ABL1 transcript levels (Mahon and Etienne 
2013). 
 
Table 1. Definition of response (Adapted from Baccarani et al. 2014) 
Hematologic Response  (HR) Complete: WBC < 10x109/L, Platelet count < 450x109/L,  
no immature granulocytes in the differential,  
and spleen non palpable. 
Cytogenetic Response (CyR) Complete (CcyR): no Ph+ metaphases  
or less than 1% BCR-ABL1 positive nuclei by I-FISH 
Molecular response (MR) 
 
MR3.0: (Major MR, MMR): BCR-ABL1 ≤ 0.1% 
MR4.0: BCR-ABL1≤ 0.01% 
MR4.5: BCR-ABL1 ≤ 0.003% 
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Previously, the goals were to obtain the complete haematological response (CHR) 
within three months of the baseline, Ph negativity or complete cytogenetic remission 
(CCyR) within 12 months of the baseline and major molecular response (MMR) within 
18 months of the baseline (Baccarani et al. 2009).  
 
The latest recommendations from European LeukemiaNet (ELN) for the treatment 
response are shown on Table 2. An optimal treatment response in CML is measured 
based on BCR-ABL1 transcript levels (Baccarani et al. 2014). Current treatments with 
TKIs are so effective that many patients can achieve such deep level response that the 
level of BCR-ABL1 is very low or even undetectable (Cross et al. 2015).   
 
Table 2. Definition of optimal response, according to ELN 2013 (Adapted from 
Baccarani et al. 2013 and 2014) 
Baseline N/A 
3 months BCR-ABL1 ≤ 10% 
and/or at least 
PCyR (Ph+ ≤ 35%) 
6 months BCR-ABL1 < 1%  
and/or 
CCyR (Ph+ 0) 
12 months BCR-ABL1 ≤ 0.1%  (MMR) 
 
Then, and at any time BCR-ABL1 ≤ 0.1%  (MMR) 
 
 
The optimal treatment response is associated with event-free survival and a good long-
term outcome, lowering the risk of disease transformation (Druker et al 2006; Baccarani 
et al. 2014). It is recommended to regularly monitor the treatment response to detect the 
early possible loss of response or any signs of disease progression (Kolibaba et al. 
2013).  
 
The consistent daily use of imatinib is important because the irregular use of medication 
can negatively affect the treatment response and result CML to progress to more 
advance phases (Druker et al. 2006; Marin et al. 2010). It is important to prevent 
chronic-phase CML to progress, because once CML has been transformed to 
accelerated or blast phases, it is more difficult to treat and to achieve CHR and CCyR 
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(Druker et al. 2006; Cortes et al. 2008; Apperley et al. 2009; Giles et al. 2012; le Coutre 
et al. 2012). Therefore, the main goal of the treatment is to prevent the transformation to 
the advanced phases and reduce the risk of death to zero (Baccarani et al. 2014). 
 
4.2 Treatment history 
 
CML has been treated for over hundred years and was first only palliative in nature 
(Hehlmann et al. 2005). Arsenic was the first medication used for the treatment of 
CML, followed by splenic irradiation, conventional chemotherapy, interferon alfa and 
allogeneic hematopoietic stem cell transplantation (alloHSCT) (Stone 2004; Hehlmann 
et al. 2005). 
 
Chemotherapy agent busulfan was a standard treatment for almost three decades 
starting from the 1950s’ (Hehlmann et al. 2005). It was shown to improve the quality of 
life within CML patients but had some serious adverse effects and did not delay the 
disease progression to accelerated phase or to blast crises (Stone 2004; Baccarani et al. 
2006). Hydroxyurea has less adverse effects than busulfan and works faster, but does 
not delay the onset of blast crises (Stone 2004). According to current recommendations, 
hydroxyurea should be used only for a short period of time before the initiation of TKI-
treatment (Baccarani et al. 2013). A recombinant interferon-alfa (rIFN-α) was brought 
to the market in the 1980s’ and was shown to induce cytogenetic remissions for 10 to 
15% of the patients and prolong the survival (Hehlmann 2005; Koskela et al. 2012). It is 
recommended that it should be used alone only in case a TKI cannot be used (Baccarani 
et al. 2013). A combination treatment of rIFN-α with TKI is being currently studied 
and it has showed some promising results (Koskela et al. 2012; Baccarani et al. 2013). 
  
The only known curable treatment for CML is allogeneic hematopoietic stem cell 
transplantation (Stone 2004; Baccarani et al. 2006). However, it has been associated 
with the significant mortality and risk of complications, and it is limited to the patients 
to whom a suitable donor can be found. The donor must have a matching human 
leukocyte antigen (HLA) (Stone 2004). Transplants from a related HLA-matched donor 
have lower mortality risk than from an unrelated donor. The number of transplants 
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within CML patients increased greatly until the end of the 1990s’ but started to drop off 
significantly in the early 2000s (Gratwohl 2006).  
 
4.3 Tyrosine kinase inhibitors 
 
4.3.1 Imatinib 
 
Tyrosine kinase inhibitor imatinib is an antineoplastic agent that selectively inhibits the 
BCR-ABL tyrosine kinase (Druker et al. 2008). Imatinib inhibits tyrosine kinase 
activity by blocking the binding site of adenosine triphosphate (ATP) to the BCR-ABL 
tyrosine kinase (Figure 2). This prevents the phosphorylation of its substrates that 
causes the excess proliferation of myeloid cells.  
 
 
Figure 2. Mechanism of action of imatinib (Druker 2008). 
 
In the IRIS study (International Randomized Study of Interferon vs. STI571) imatinib 
was compared with rIFN-α  and low-dose cytarabine for newly diagnosed CML 
patients as first line therapy (O’Brien et al. 2003). With regard to hematologic and 
cytogenetic responses, the rate of disease progression and tolerance, Imatinib was 
superior to the compared treatment. It induces major molecular remission in the 
majority of CML patients, increases the long-term survival and has generally good 
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safety and adverse-events profile (Druker 2008; Baccarani et al. 2014). When imatinib 
was brought to the market in 2001, it caused a dramatic change in the management of 
CML (Baccarani et al. 2006). Since its introduction, Imatinib has become a standard 
treatment for CML and significantly improved the outcomes for the patients (Saglio et 
al. 2010). 
 
4.3.2 Second-generation tyrosine kinase inhibitors 
 
Since the introduction of imatinib, three second generation TKIs nilotinib, dasatinib and 
bosutinib, and one third generation ponatinib have been developed (Baccarani et al. 
2009; Jabbour et al. 2015). Based on the clinical trials nilotinib and dasatinib are more 
potent and more effective than imatinib and have higher and more rapid cytogenetic and 
molecular response rates in newly diagnosed CML patients (Saglio et al. 2010; 
Kantarjian et al. 2010). They were initially recommended for the treatment as second 
line therapy for patients with a suboptimal treatment response to imatinib, imatinib 
intolerance or for patients who had developed resistance to imatinib (Baccarani et al. 
2009).  
 
4.3.3 Administration and dosing 
 
According to current treatment guidelines by European LeukemiaNet any of the three 
TKIs imatinib, dasatinib or nilotinib can be used as first-line treatment for chronic phase 
(CP) CML (Baccarani et al. 2013). The recommended dosages and administration of 
each agent are listed on table 3. 
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Table 3. The recommended starting dosage of imatinib, nilotinib and dasatinib for CP-
CML (Adapted from Summary of product characteristics of  (2006), Sprycel (2011) and 
Tasigna (2012). 
TKI  Dosage Administration 
Imatinib 
(Glivec®) 
400 mg once daily. 
Can be increased to a maximum 
of 800 mg (given as 400 mg twice 
daily) 
The dose should be taken with a meal and 
a glass of water to reduce gastrointestinal 
irritations. 
Nilotinib 
(Tasigna®) 
300 mg twice daily The dose should be taken in to an empty 
stomach, 1 hour before or 2 hours after 
food. The capsules should be swallowed 
whole with water. Alternatively the 
capsule can be opened and mixed with 
one teaspoonful of applesauce. 
Dasatinib 
(Sprycel®) 
100 mg once daily.  
Can be increased to a maximum 
of 180 mg once daily 
The dose can be taken with or without a 
meal. The tablets should be swallowed 
whole. 
 
 
4.3.4 Adverse drug reactions 
 
Tyrosine kinase inhibitors are relatively well tolerated and common non-hematological 
adverse drug reactions (ADRs) are generally mild to moderate (grade 1-2) (Kantarjian 
et al. 2010; Mughal et Schrieber 2010; Saglio et al. 2010). Imatinib, nilotinib and 
dasatinib have similar types of ADR profiles, but the relative occurrence of ADRs 
differs between each agent. Some of the most commonly reported non-hematological 
ADRs in clinical trials are reported in Table 4 (not exhaustive). Frequencies of ADRs 
are defined as: very common (≥1/10) and common (≥1/100 to <1/10). Cytopenias of all 
grades, particularly neutropenia, thrombocytopenia and anemia are very common with 
imatinib, nilotinib and dasatinib (Table 5) (Summary of product characteristics of 
Glivec 2006, Sprycel 2011 and Tasigna 2012).  
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Table 4. Commonly reported adverse drug reactions (ADRs) of imatinib, dasatinib and 
nilotinib; very common (≥1/10) and common (≥1/100 to <1/10). Adapted from 
Summary of product characteristics of  Glivec (2006), Sprycel (2011) and Tasigna 
(2012). 
System organ class 
ADR 
Imatinib 
(Glivec®) 
Dasatinib 
(Sprycel®) 
Nilotinib 
(Tasigna®) 
Infections and infestations 
Infection 
Pneumonia 
Upper respiratory tract infection 
  
Very common 
Common 
Common 
 
 
 
Common 
Blood and lymphatic system 
disorders 
Neutropenia 
Thrombocytopenia 
Anaemia 
Leukopenia 
 
 
Very common 
Very common 
Very common 
 
 
Very common 
Very common 
Very common 
 
 
Very common 
Very common 
Common 
Common 
Metabolism and nutrition 
disorders 
Hypophosphataemia 
Anorexia 
Apetite disturbances 
 
 
 
Common 
 
 
 
 
Common 
 
 
Very common 
 
Common 
Psychiatric disorders 
Depression 
Insomnia 
Anxiety 
 
 
Common 
 
Common 
Common 
 
Common 
Common 
Common 
Nervous system disorders 
Headache 
Dizziness 
Hypoesthesia 
 
Very common 
Common 
Common 
 
Very common 
Common 
 
 
Common 
Common 
Eye disorders 
Eyelid oedema 
Conjuctivitis 
Dry eyes 
Blurred vision 
 
Common 
Common 
Common 
Common 
 
 
 
Common 
Common 
 
 
Common 
Common 
Ear and labyrinth disorders 
Tinnitus 
Vertigo 
  
Common 
 
 
Common 
Vascular disorders 
Haemorrhage 
Flushing 
 
Common 
Common 
 
Very common 
Common 
 
 
Common 
Respiratory, thoracic and 
mediastinal disorders 
Dyspnoea 
Pleural effusion 
Cough 
 
 
Common 
 
Common 
 
 
Very common 
Very common 
Common 
 
 
Common 
 
Common 
Gastrointestinal disorders 
Nausea 
Diarrhoea 
Vomiting 
Dyspepsia 
Abdominal pain 
 
Very common 
Very common 
Very common 
Very common 
Very common 
 
Very common 
Very common 
Very common 
Common 
Very common 
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Abdominal distension 
Abdominal discomfort 
Flatulence 
Gastritis 
Contipation 
Dry mouth 
Common 
 
Common 
Common 
Common 
Common 
Common 
 
 
Common 
Common 
 
Common 
Common 
 
Skin and subcutaneous tissue 
disorders 
Periorbital oedema 
Rash 
Dermatitis/eczema 
Hyperhidrosis 
 
 
Very common 
Very common 
Very common 
 
 
 
 
Very common 
Common 
Common 
 
 
 
 
Common 
Common 
Musculoskeletal and connective 
tissue disorders 
Muscle spasm 
Musculoskeletal pain 
Bone pain 
Muscular weakness 
 
 
Very common 
Very common 
Very common 
 
 
 
Common 
Very common 
Very common 
Common 
 
 
 
 
Common 
Common 
General disorders and 
administration site conditions 
Fluid retention and oedema  
Fatigue 
 
 
Very common 
Very common 
 
 
Very common 
Very common 
 
 
 
 
 
 
Table 5. Percentages of common hematologic abnormalities (all grades and grade 3/4) 
(Adapted from O’Brien et al. 2003; Kantarjian et al. 2010; Saglio et al. 2010) 
 Imatinib 400 mg once daily 
Nilotinib 
300 mg twice daily 
Dasatinib 
100 mg once daily 
All grades 
(%) 
Grade ¾ 
(%) 
All grades 
(%) 
Grade ¾ 
(%) 
All grades 
(%) 
Grade ¾ 
(%) 
Neutropenia 61 14 43 12 65 21 
Thrombocytopenia 57 8 48 10 70 19 
Anemia 45 3 38 3 90 10 
 
 
4.3.5 Discontinuation of the treatment 
 
Several studies have been conducted to find out about the possibility for the 
discontinuation of imatinib for the patients who have had long-lasting, deep molecular 
response (Mahon et al. 2010; Baccarani et al. 2013; Branford et al. 2013). Of the 
patients who discontinued imatinib, approximately 40% maintained the same degree of 
response during the follow-up period of one to four years (Baccarani et al. 2013). 
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Almost all of the patients who had a molecular relapse were able to achieve the same 
level of a deep molecular response that they had prior the study, after they restarted 
imatinib. These findings suggest that it is possible to discontinue imatinib without a 
molecular relapse in some patients, who are carefully selected (Mahon et al. 2010; 
Baccarani et al. 2013; Branford et al.2013). 
 
4.4 Health-related quality of life 
 
Assessing health-related quality of life (HRQOL) is important within CML patients and 
is one of the key outcomes when comparing different treatment options on clinical 
decision-making (Efficace et. al 2011). Few studies have studied the quality of life 
(QoL) of CML patients and most of them are done with patients treated with TKIs 
(Efficace et al. 2011; Phillips et al. 2013; Trask et al. 2013). In the IRIS study, QoL was 
assessed with CML patients who were randomly assigned to receive imatinib or 
subcutaneous interferon alfa plus low dose cytarabine (IFNα+LDAC) (Hahn et al. 
2003). The primary goal was to measure patient’s wellbeing and physical function. The 
study found that the patients who were treated with imatinib had significantly higher 
QoL compared to the patient treated with IFNα+LDAC.  
 
Even though TKIs have relatively good adverse-event profiles, they have a number of 
ADRs, which can have an impact on CML patients’ QoL (Phillips et al. 2013). In a 
study comparing QoL of CML patients treated with TKIs to controls who were age and 
gender-matched and who had no history of cancer, CML patients had worse physical 
QoL, more fatigue, depression, anxiety and greater symptom burden. In another study, 
especially in younger patients aged between 18 and 39 had worse HRQOL, compared to 
the general population (Efficace et al. 2011) Young patients had noticeable limitations 
in work or other daily activities because of physical and emotional problems. In the 
same study female patients had a generally worse HRQOL profile than men, compared 
to control population.  
 
According to the patient data that was also used in this master’s thesis, half of the study 
patients reported that ADRs of the TKI treatment had negative influence on their daily 
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QoL (Kekäle et al. 2015). These patients suffered from an average of eight different 
symptoms. A number of patients felt that ADRs affected either on their mood, the 
enjoyment of life or general condition. Men were more likely to report about symptoms 
impacting negatively in their daily life than women. One study has compared the 
HRQOL of CML patients to their first, second or third line treatments as well as 
patients with chronic phase (CP) CML, accelerated phase (AP) CML and blast phase 
(BP) CML (Trask et al. 2013). Patients with advanced phase CML had generally poorer 
HRQOL compared with patients in CP CML. Physical well-being and Leukemia 
subscale that assess patient’s concerns about leukemia were worse for patients in 
second- or third-line therapy. 
 
 
5 ADHERENCE  
 
Adherence to therapy plays an important role in obtaining the optimal treatment 
outcome (Marin et al. 2010). Poor adherence can be a major obstacle in long-term 
therapies affecting the effectiveness of the treatment (The World Health Organization 
2003). Optimal adherence occurs when a patient takes a correct dose at a correct time 
and does not miss any doses or take extra doses (Ruddy et al 2009).  
 
5.1 Adherence – terminology and definitions 
 
A number of different terms have been used to describe the concept of medicine taking 
and following a treatment regimen (National Institute for Health and Clinical 
Excellence 2005; Cramer et al. 2008). The terms “adherence”, “compliance”, 
“concordance” and “persistence” are often used and it is important to understand the 
differences between the definitions.  
 
Adherence has been defined as “the extent to which a person’s behaviour – taking 
medication, following a diet, and/or executing lifestyle changes, corresponds with 
agreed recommendations from a health care provider” (The World Health Organization 
2003). Compliance has been referred to as “the extent to which the patient’s behaviour 
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matches the prescriber’s recommendations” (National Institute for Health and Clinical 
Excellence 2009). The term compliance has been traditionally used to describe 
medicine taking. It suggests that the role of the prescriber is to decide on the correct 
medication and the role of patient is to passively follow the doctor’s order. However, 
National Institute for Health and Clinical Excellence (2009) recommends “adherence as 
the term of choice to describe patients’ medicine taking behaviour”.  The term 
adherence highlights the agreement between the patient and the physician about the 
prescriber’s recommendation (The World Health Organization 2003). 
 
Concordance is defined as the interaction between clinician and patient, assuming that 
both negotiating parties are equals (Bell et al. 2007). Thus, it does not refer to patient’s 
medication-taking behaviour (National Institute for Health and Clinical Excellence 
2009). In concordance patients participate in their own healthcare, which could 
potentially improve adherence but not necessarily. Persistence describes the 
continuation of the treatment for the prescribed duration and has been defined as “the 
duration of time from the initiation to discontinuation of therapy” (The International 
Society for Pharmacoeconomics and Outcome Research ISPOR) (Cramer et al. 2008). 
Non-persistence occurs if the patient is not taking his or her medication as long as it is 
prescribed (Ruddy et al. 2009).  
 
5.2 Prevalence of non-adherence 
 
Nonadherence to the long-term therapy is a significant problem both in developed and 
developing countries (The World Health Organization 2003). It has been estimated that 
nonadherence among patients with chronic conditions can be as high as 50% in 
developed countries and even higher in developing countries. Even though cancer is a 
serious disease, non-adherence also occurs within the cancer patients (Atkins and 
Fallowfield 2006; Ruddy et al. 2009).  
 
Nonadherence should not be considered as the patient’s problem but instead as 
limitation in delivering healthcare services (National Institute for Health and Clinical 
Excellence 2009). This can happen when a patient does not fully agree with the 
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prescription in the first place or patient does not receive the support she or he may need. 
For example, in the fear of displeasing a physician, patients might not bring up doubts 
or concerns they have about the treatment. In addressing nonadherence, it is important 
to understand patients’ attitudes towards medications and the reasons for nonadherence, 
whether it is intentional or unintentional.  
 
5.3 Factors related to non-adherence 
 
Several factors can affect nonadherence and reasons can be complicated (Patridge et al. 
2002; Ruddy et al. 2009). Nonadherent behaviour can be influenced by the patients 
themselves, including personal and sociodemographic characteristics, or by factors that 
are related to the illness and treatment regimen or healthcare system (Figure 3) (Ruddy 
et al. 2009; Jabbour et al. 2012). 
 
Figure 3. Model of non-adherence (Adapted from Ruddy et al. 2009; Jabbour et al. 
2012) 
 PATIENT 
Health beliefs and expectations of 
treatment 
Psychological & emotional factors 
No understanding of risks and 
benefits of treatment 
Conscious decision 
Social support 
INTERACTION WITH 
HEALTHCARE TEAM 
Satisfaction with care 
Poor communication or 
relationship with patient 
Poor patient education 
Insurance coverage 
 
TREATMENT  
Reasons for therapy 
Frequency/complexity of 
dosing 
Immediacy and evidence of 
benefits 
Time from diagnosis 
Side effects 
Costs 
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Both internal and external factors can influence on medicine taking and adherence 
(National Institute for Health and Clinical Excellence 2009). Internal factors can be, for 
example, patient’s beliefs and experiences about their symptoms, disease or medication 
and medications in general. Patients’ might be concerned about long-term medication 
use, the harmful effects of medications in general or overuse of medications and this 
have been associated with nonadherence (Phatak et Thomas, 2006). Communication 
with family, friends and their health care provider and the information they receive from 
different healthcare practitioners are examples of external factors (National Institute for 
Health and Clinical Excellence 2009). The attitude in society toward medications or 
condition can also affect on patient’s adherence. 
 
Non-adherence can be intentional or unintentional (National Institute for Health and 
Clinical Excellence 2009). Unintentional nonadherence means that a patient is willing 
to adhere to treatment but fails to do so because of the factors that are beyond their 
control. A patient can, for example, forget to take the prescribed medication, 
misunderstand the instructions, not afford to pay the medications, have difficulties in 
taking the medication (National Institute for Health and Clinical Excellence 2009) or it 
can be due to prescribing error (Eliasson et al. 2011).  Intentional nonadherence means 
that patients decide not to take their medication as prescribed by their physician 
(National Institute for Health and Clinical Excellence 2009). This can happen even 
when patients are fully aware of the risks and consequences of not taking their 
medications as prescribed. For instance, a factor that could contribute intentional 
adherence is experienced ADRs (Eliasson et al. 2011).  
 
5.4 Measures of adherence 
 
While planning an effective treatment regimen, it is important to assess adherence and 
to identify patients’ needs for more information or support (The World Health 
Organization 2003; National Institute for Health and Clinical Excellence 2009).  There 
is a variety of methods of measuring medication adherence and they fall under two 
categories: direct and indirect methods (National Institute for Health and Clinical 
Excellence 2009).  Each of the measures has limitations, thus measuring adherence 
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accurately is difficult (National Institute for Health and Clinical Excellence 2005; 
Partridge et al. 2002). 
 
5.4.1 Direct Methods 
 
Direct methods include evidence that medication has been taken, such as detecting a 
medicine, a metabolite or a biological marker in patient’s blood, urine or other fluids 
(Hawkshead & Krousel-Wood 2007). However, such levels can vary because of 
individual pharmacokinetics (Ruddy et al. 2009). Also, patients who are nonadherent 
could manipulate results by taking additional doses just before a visit to the office to 
hide their nonadherent behaviour.  
 
5.4.2 Indirect methods 
 
Indirect methods include pill counts, pharmacy refill records, electronic medicine 
monitoring (EMM) and patient’s self-report (National Institute for Health and Clinical 
Excellence 2009). Pill count is a simple, inexpensive method, where adherence can be 
measured by counting the tablets patients have left at the end of a certain time frame 
and to compare that with the total number of tablets they had received, (Hawkshead & 
Krousel-Wood 2007) Pill count provides accurate information on missed doses, but 
won’t specify information regarding when and what time the doses were taken (The 
World Health Organization 2003; Lee et al. 2007).  
 
A pharmacy dispensing records can be utilized by using prescription refill rates for 
measuring adherence (Hawkshead & Krousel-Wood 2007). In this method initial fill, 
refills and possible discontinuation can be checked (The World Health Organization 
2003) as well as possible delays in refill (Hawkshead & Krousel-Wood 2007). One of 
the advantages is that when patients do not know that their adherence is assessed, it will 
not affect on their medication-taking behaviour (Hawkshead & Krousel-Wood 2007). 
However, the method will not tell if the patients actually take their medications (The 
World Health Organization 2003). A medication possession ratio (MPR) can be 
calculated using a pharmacy prescription database and it shows the proportion of 
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medication supply that has been filled during a certain time period (Lam and Fresco 
2015). It is a simple way of measurement but can overestimate adherence. 
 
A medication event monitoring system (MEMS) is an electronic adherence monitoring 
system, which records the time and date every time the medication bottle is opened 
(Lam and Fresco 2015). It is very accurate in measuring adherence but the high costs of 
the devices limit the wider use. 
  
Self-report, such as a patient-kept medication diary, interview or a questionnaire, is a 
simple, quick and inexpensive way to measure adherence in clinical settings 
(Hawkshead & Krousel-Wood 2007; National Institute for Health and Clinical 
Excellence 2009).  Self-report provides information about behavioural, social and 
situational factors, and thus, can help in identifying the underlying causes of 
nonadherence. However, self-reporting can be inaccurate because of recall bias or over-
estimating adherence (Hawkshead & Krousel-Wood 2007). The way questions are 
asked and what words are used can be confusing and the skills of the interviewer can 
affect on the validity of the self-report assessment (Hawkshead & Krousel-Wood 2007; 
National Institute for Health and Clinical Excellence 2009). There are a number of 
multi-item questionnaires available to provide a valid and reliable method of measuring 
medication adherence (Hawkshead & Krousel-Wood 2007). If patients are aware that 
their adherence is being assessed, it can affect their behaviour and may therefore 
improve the level of adherence (Ruddy et al. 2009). This is known as the “Hawthorne 
effect”. 
 
5.4.3 Morisky Medication Adherence Scale 
 
Morisky et al. (1986 and 2008) have developed a structured four-item and eight-item 
self-reported Medication Adherence Scale (MMAS-4 and MMAS-8) for identifying 
patients with adherence problems. The adherence measure is easy to use during medical 
visits; it can be used in an initial adherence assessment as well as for monitoring 
adherence over the course of the continuous treatment. The original MMAS-4 was 
developed and validated to measure adherence in patients with high blood pressure 
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(Morisky et al. 1986). The items in the scale are designed to address barriers to 
medicine taking and provide a tool for health care practitioners to reinforce positive 
adherence behaviour (Table 6). Patients tend to give positive answers to their physicians 
or other healthcare providers (HCPs) when asking about adherence and the wording in 
the questions are designed this in mind. Wording has been composed so that the “yes” 
answers would indicate nonadherence. The concurrent and predictive validity of the 
scale was tested with patients receiving blood pressure medications. Their blood 
pressure results and adherence data were recorded after 2-year and 5-year follow-up 
from 290 patients. The results showed that the patients who had high adherence at two 
years were more likely to have their blood pressure under the control at five years 
compared with nonadherent patients. 
 
Table 6. Self reported 4-Item Morisky Medication Adherence Scale (MMAS-4) 
(Adapted from Morisky et al. 1986) 
1. Do you ever forget to take your medicine? 
2. Are you careless at times about taking your medicine? 
3. When you feel better do you sometimes stop taking your medicine? 
4. Sometimes if you feel worse when you take the medicine, do you stop taking it? 
Scoring: high - low; yes = 0; no = 1; Range: 0-4 
 
 
MMAS-8 was developed from a MMAS-4 questionnaire to include more questions to 
address different aspects of adherence behaviour (Morisky et al. 2008). The 
questionnaire consists of 8 questions and each of them measures a specific medication-
taking behaviour (Table 7). As in the previous 4-item scale, the questions are composed 
so that possible yes-saying biases can be avoided. The questionnaire consists of seven 
questions with yes/no responses and one 5-point Likert response. Scores range from 0 to 
8, where a score of 8 on the scale indicates high adherence, a score of 6 to < 8 medium 
adherence and a score of < 6 low adherence. The psychometric properties and the 
concurrent and predictive validity were tested in total of 1367 patients with 
hypertension over the 6-months follow-up period. The results showed that the scale was 
reliable and there was a significant association between higher adherence and blood 
pressure being under control. The MMAS-8 was found to have higher sensitivity than 
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MMAS-4 indicating that it is reliable in assessing adherence and behavioural and 
attitudinal problems that are related to the treatment regimen. However, as with other 
self-reports, disadvantages are that patients can overestimate their adherence or might 
not recall answers correctly. 
 
Table 7. Self reported 8-Item Morisky Medication Adherence Scale (MMAS-8) 
(Adapted from Morisky et al. 2008) 
1. Do you sometimes forget to take your high blood pressure pills? 
2. Over the past 2 weeks, were there any days when you did not take your high blood 
pressure medicine? 
3. Have you ever cut back or stopped taking your medication without telling your doctor 
because you felt worse when you took it? 
4. When you travel or leave home, do you sometimes forget to bring along your 
medications? 
5. Did you take your high blood pressure medicine yesterday? 
6. When you feel like your blood pressure is under control, do you sometimes stop 
taking your medicine? 
7. Taking medication everyday is a real inconvenience for some people. Do you ever 
feel hassled about sticking to your blood pressure treatment plan? 
8. How often do you have difficulty remembering to take all your blood pressure 
medication? 
 
Scoring: Yes = 0; No = 1; Item 8 contains 5 item Likert scale (Never/Rarely = 1; Once in a 
while = 0.75, Sometimes = 0.50, Usually = 0.25, All the time = 0). 
 
 
MMAS-8 was initially developed to use among hypertension patients but the 
questionnaire is suitable for measuring medication adherence within other conditions as 
well. It has been modified and validated for different conditions such as osteoporosis 
(Reynolds et al. 2012), type 2 diabetes (Sakthong et al. 2009) and Parkinson’s disease 
(Fabbrini et al. 2013). MMAS-8 has been translated and validated in number of 
different languages, for example French (Korb-Savoldelli et al. 2012), Italian (Fabbrini 
et al. 2013) and Malay (Malaysian language) (Al-Qazaz et al. 2010), which well 
describes its widespread use internationally. It has been also translated into Finnish and 
used to measure adherence in Finnish CML patients; the same data that is used in this 
master’s thesis (Kekäle et al. 2014). 
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6 ADHERENCE TO TYROSINE KINASE INHIBITORS IN CHRONIC 
MYELOID LEUKEMIA PATIENTS 
 
The discovery of TKIs has dramatically changed the outcomes for CML patients. To 
current knowledge, the use of TKI is possibly a lifelong treatment and requires 
medicine taking on a daily basis with continuous and adequate dosing (Noens et al. 
2009; Baccarani et al. 2013). Thus, adherence is utmost important in optimizing the best 
possible treatment outcomes. Poor adherence can have serious consequences; non-
adherence has been associated to significantly lower molecular response rates in CML 
patients increasing the risk for disease progression (Noens et al. 2009; Marin et al. 
2010; Ibrahim et al. 2011). It can also lead to increased health care costs (Darkov et al. 
2007). 
 
To identify previous studies assessing poor adherence to TKIs within CML patients, 
searches in PubMed, Medline and Google Scholar was used using various key terms 
and their combinations. These were adherence, nonadherence or compliance and 
tyrosine kinase inhibitors, chronic myeloid leukemia, imatinib, dasatinib, nilotinib, 
response and treatment outcome. More studies were found in the references of the 
studies found in initial search.  
 
6.1 Prevalence of non-adherence and clinical treatment outcomes 
 
The severity of CML could be regarded as a motivating factor for patients to adhere to 
their treatment. For this reason doctors often assume that cancer patients take their 
medications as prescribed and hence do not ask a patient about their medication-taking 
behaviour (Partridge et al. 2002; Timmers et al. 2014). Nevertheless, poor adherence is 
more common than physicians or patients themselves even realize (Noens et al. 2009).  
Several studies have shown that lack of adherence to TKIs within CML patients is 
common, ranging from 3% to 47% (Noens et al. 2009; Marin et al. 2010; Eliasson et al. 
2011, Jönsson et al. 2011, Efficace et al. 2012). In Table 8 are included all studies found 
in literature search, which have both measured CML patients’ nonadherence and 
assessed factors related to nonadherence. 
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Table 8. The prevalence of CML patients’ nonadherence to TKIs and factors related to nonadherence (Darkov et al. 2007; Noens et al. 2009; Marin et 
al. 2010; Eliasson et al. 2011, Jönsson et al. 2011, Efficace et al. 2012; Anderson et al. 2015; Kapoor et al. 2015) 
Author 
Publication year 
Country TKI How adherence was 
measured 
Nonadherence rate 
(%) 
Findings 
Darkov et al. 2007 USA Imatinib MPR, 
Prescription refill 
record 
46% had a MPR <90% 
20% had a MPR <50% 
31% had treatment 
interruptions 
MPR was lower among patients with more concomitant 
medications, women, patients with high cancer complexity and 
patients with the higher starting dose of imatinib. 
Noens et al. 2009 Belgium Imatinib BAAS,  
VAS (rated by 
physicians, patients 
and third persons), 
pill count 
At baseline 
BAAS: 36% 
VAS rating by physicians, 
patients and third 
persons: 94.9-97.0 
Pill count: 29% - 202% 
of prescribed dose at 
follow-up 
Weak correlations were observed between the number of 
adverse events and patient and third person perception of 
adherence and adherence behaviour. Higher age, time since 
diagnosis, living alone and male sex was associated with 
nonadherence.  
Knowledge of disease and treatment, more medications and 
higher education was associated with better adherence. 
No significant associations were found between the adherence 
behaviour and the length of illness, the duration of the treatment, 
sex, the quality of chronic care, functional status or the quality of 
life. There were no significant associations of adverse events, a 
number of patients reported symptoms and bothersomeness of 
these symptoms with pill count adherence. 
Marin et al. 2010 UK Imatinib MEMS 26% had adherence 
rate ≤90% 14% ha adherence rate 
≤80% 
 
Low adherence was associated with younger age, adverse 
effects (asthenia, nausea, muscle cramps and bone or joint pain) 
and unexplained increase in BCR-ABL1 transcript levels.  
There was no association between adherence and the length of 
imatinib treatment or sex. 
Eliasson et al. 
2011 
UK Imatinib MEMS 26% Reasons for unintentional nonadherence were forgetting, 
accidentally talking too much and no imatinib available at 
pharmacy. 
Reasons for intentional nonadherence were minimizing side 
effects, travelling or going for a holiday and socializing. 
Reasons for being adherent were doing what doctor says, faith 
in clinician and imatinib and no experienced side effects. 
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Jönsson et al. 2011 Sweden Imatinib 9-MMAS 3% Patients showed good adherence, were well informed, had 
frequent contact with a single hematologist, had easy access to 
the treating clinic and felt that they took part in decisions 
regarding treatment 
Efficace et al. 2012 Italy Imatinib MMAS* 47% Concomitant drug burden, greater level of social support and 
satisfaction with information received predicted greater 
adherence.  
There were no associations between adherence and age, 
gender, education, marital status, intolerance to imatinib therapy 
or duration of therapy. 
Roosevelt et al. 
2012 
Brazil Imatinib MPR 47% Reasons for treatment interruptions were unavailability of 
medication, grade 3 and 4 hematologic ADRs, non-hematologic 
ADRs, missed appointment, taking a lower-than prescribed 
dose, forgetting, social events and financial difficulties. 
Anderson et al. 
2015 
Canada Imatinib, 
dasatinib, 
nilotinib 
MPR 31% Patients on concurrent medications were more likely to be 
adherent. Median MPR was significantly lower in patients under 
50 years old and patients treated with imatinib compared to 
nilotinib and dasatinib. No relationship was found between 
adherence and sex, side effects, years of treatment, residence 
or previous treatment with interferon. 
Kapoor et al. 2015 India Imatinib 9-MMAS and  
additional 
questionnaire 
25% High adherence was associated with income, no prevalence of 
depression and no concomitant drug burden. 
There was no association between adherence and sex, age, 
knowledge about medicine and disease, social support, 
education, employment status, side effects, polypharmacy or 
dosage. 
MPR = Medication possessing ratio; BAAS = Basel assessment of adherence with immunosuppressive medication, adapted to imatinib; VAS = Visual analog scale 
converted 1 to 100 score; MEMS = Medication events monitoring system; 9-MMAS = 9 item Morisky medication adherence scale; MMAS* = Adapted version of 4 
item Morisky medication adherence scale, with 3 questions 
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Most data regarding adherence to TKIs have primarily studied with imatinib (table 8). 
Few studies have compared adherence in patients receiving imatinib, dasatinib or 
nilotinib (Santoleri et al. 2012; Anderson et al. 2015). An observational, retrospective 
study of 91 patients evaluated the adherence of patients treated with first line imatinib 
or second line dasatinib and nilotinib (Santoleri et al. 2012).  The study found that 
nonadherence rates were 17% for the patients with imatinib, 15% for the patients with 
dasatinib and 7% for the patients with nilotinib. Persistence was also evaluated, for 
which the rates were 90%, 80% and 83%, respectively, stating that while patients with 
imatinib were less adherent, they were more persistent on their treatment. In a 
descriptive study of 124 patients, 31% were nonadherent to TKI treatment and 
medication possession ratio (MPR) was significantly lower in patients treated with 
imatinib compared to dasatinib and nilotinib (Anderson et al. 2015). 
 
In the multicenter observational study of 169 CML patients treated with imatinib, one-
third of the patients were nonadherent, 71% of the patients took imatinib less than 
prescribed and 15% more than prescribed (Noens et al. 2009). Only 14% were found to 
be fully adherent based on the pill counts. Patients with a suboptimal treatment response 
were more likely to be nonadherent based on the pill count, compared with patients with 
an optimal response. Among patients who had been taking imatinib for at least 12 
months, those who had incomplete CyR had significantly higher mean percentages of 
imatinib not taken compared to patients with CCyR. In another prospective 
observational study of 87 patients with chronic phase CML, a median adherence rate 
was 98% ranging from 24% to 104%, based on MEMS (Marin et al. 2010). There was a 
strong correlation between the adherence to imatinib and the molecular response. 
Patients with adherence rate ≤ 90% did not achieve a complete molecular response 
(CMR) and with adherence rate ≤ 80% did not achieve a major molecular response 
(MMR). The study proposed that adherence rate of  >90% was adequate to predict a 
good treatment outcome. 
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6.2 Non-adherence and economic outcome 
 
Although CML patients’ poor adherence to TKI treatment has been recognized to be a 
common problem in several studies, its impact on an economic outcome has not been 
studied much. In literature search two studies were found studying the impact of 
nonadherence to health care costs (Darkow et al. 2007; Wu et al. 2010). According to 
Darkov et al. 2007 there is clear evidence that nonadherence and treatment interruptions 
with imatinib have been associated with increased health care costs. In a retrospective 
analysis treatment interruptions and nonadherence with imatinib was studied in the US 
with 267 patients during a 12-month follow-up. Treatment interruptions and 
nonadherence were identified using electronic healthcare claims data and MPR. There 
was a strong association with higher MPR and lower total medical costs, which 
consisted of the costs for all medical services and prescription medications, and lower 
healthcare costs, which excluded imatinib. Pharmacy expenses can be higher for more 
adherent patients because of the high cost of imatinib, whereas the overall health care 
costs seem to be lower due to lower inpatient hospitalization rates. Similar results were 
found in another study evaluating the association between nonadherence to imatinib 
treatment and healthcare resource utilization and costs (Wu et al. 2010). High adherence 
was associated with significantly lower resource utilization and costs. Nonadherent 
patients had more all-cause inpatient visits and days and also significantly higher 
healthcare cost excluding imatinib, compared to patients with higher adherence.  
 
6.3 Factors related to non-adherence 
 
Several studies have been conducted to identify factors predicting non-adherence in 
CML patients (Table 8). Results are more or less inconsistent indicating that a number 
of factors may influence adherence and that there is not always clear association 
between a patient, disease or treatment related factors and nonadherence.  
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6.3.1 Patient related factors 
 
Contradictory results have been reported from several studies regarding the role of age 
and gender as predictors for nonadherence. While some studies have found association 
between gender or age and adherence (Darkov et al. 2007; Noens et al 2009; Marin et 
al. 2010), several studies have reported no association at all (Efficace et al. 2012; 
Anderson et al. 2015; Kapoor et al. 2015). Higher education can indicate better 
adherence according to one study (Noens et al. 2009), while in a few other studies there 
was no association between education and adherence (Efficace et al. 2012; Kapoor et al. 
2015). Marital status has not shown to affect adherence (Efficace et al. 2012) aside from 
one study in which patients living alone were more likely to be nonadherent (Noens et 
al. 2009). Income has shown to affect adherence in an Indian study (Kapoor et al. 
2015). This could be because of patients can not afford to buy the expensive medication 
in the country, where a number of people may not have medical insurance or public 
health care system is not covering the costs. 
 
Forgetfulness (Eliasson et al. 2011) and ADRs have been shown to be the most 
common reason for nonadherence (Noens et al. 2009; Marin et al. 2010; Roosevelt et al. 
2012). Patients may make decisions about medication-taking based on their perception 
and knowledge of the condition and treatment (Noens et al 2009; Eliasson et al. 2011). 
Patients’ knowledge of CML and its treatment and also faith in imatinib have been 
associated with better adherence (Noens et al. 2009; Eliasson et al. 2011; Jönsson et al. 
2011; Efficace et al. 2012). Understanding how the treatment works could motivate 
patients to better adherence.  Patients with self-efficacy in long-term medication 
behaviour have reported to have higher adherence to imatinib (Noens et al. 2009). In 
this, self-efficacy refers to a patient’s level of confidence in being able to adhere to 
long-term treatment. Often patients do not think that missing a dose a few times could 
have an impact on their response to imatinib while some believe that only if missing a 
dose for a longer time of period could affect negatively on the treatment outcome  
(Eliasson et al. 2011). Patients may think that after starting to take imatinib again it will 
start working right away (Eliasson et al. 2011).  
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Mental wellbeing, no prevalence of depression and greater level of social support from 
friends, family members and significant others can contribute better adherence (Efficace 
et al. 2012; Kapoor et al. 2015). ADRs and the inconvenience of imatinib therapy can 
impact on patients’ social life, holidays or travelling, contributing to intentional 
nonadherence (Eliasson et al. 2011). However, in the same study, some of the patients 
who described how ADRs from imatinib therapy led to tensions with family and friends 
and affected on their daily activities, still took their medication as prescribed. Reasons 
for this were having faith in the doctor and willingness to do what doctor prescribed. In 
another study, patients who expressed that CML has significantly affected their daily 
life, such as work, family life and leisure activities, still showed good adherence 
(Jönsson et al. 2011). In this study majority of the patients thought that they were able 
to participate in treatment related decisions and that their actions had an impact on the 
clinical outcome. 
 
6.3.2 Treatment related factors 
 
Experienced ADRs are common treatment-related reasons for nonadherence (Marin et 
al. 2010; Eliasson et al. 2011; Efficace et al. 2012). Nausea, asthenia, muscle cramps 
and bone or joint pain were mentioned by the patients who reported low adherence rates 
(Marin et al. 2010; Eliasson et al. 2011).  Concomitant medications could predict either 
increasing or decreasing adherence. In some studies concomitant medications have been 
associated with higher adherence (Noens et al. 2009; Efficace et al. 2012; Anderson et 
al. 2015) while couple other studies have reported the opposite findings (Darkov et al.; 
Kapoor et al. 2015. Based on several studies higher imatinib dose (≥ 600 mg/day) or 
cancer complexity can lead to lower adherence (Darkov et al. 2007; Noens et al. 2009; 
Marin et al.2010).  
 
6.3.3 Physician and healthcare related factors 
 
Few studies have covered the influence of a physician or healthcare related factors on 
adherence within CML patients. In the study where CML patients had a very low 
nonadherence rate to TKIs, a majority of the patients had the same hematologist in the 
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follow-up appointments and thought that they had been well informed about CML by 
their hematologist and had an average very good knowledge about the disorder (Jönsson 
et al. 2011). Faith in clinician and willingness to follow physician’s orders can have a 
positive effect on adherence (Eliasson et al. 2011).  
 
Poorly organized health services can have a negative effect on adherence (The World 
Health Organization 2003; Verbrugghe et al. 2013). A shorter duration of appointment 
times, not enough follow-ups and overworked healthcare staff or fail to provide 
community support for the patients have been associated with nonadherence. This could 
make patients feel that their care is not being managed properly enough, which could 
potentially affect their own attitude towards the importance of the treatment. 
 
 
 
EMPIRICAL PART 
 
Factors Related to Poor Adherence to Oral Tyrosine Kinase Inhibitor Treatments 
in Chronic Myeloid Leukemia Patients in Finland 
 
CML is a rare but serious disease that can be kept under control by using TKI treatment. 
Good adherence to TKI therapy is important in obtaining the optimal treatment outcome 
and preventing disease from progressing. However, several international studies have 
shown that nonadherence is common within CML patients. This study is part of a larger 
study, the doctoral thesis by Meri Kekäle, assessing adherence to TKI treatment among 
Finnish CML population. The study population consisted of 86 Finnish CML patients 
who were treated either with imatinib, dasatinib or nilotinib. Based on the MMAS-8 
questionnaire 18 out of 86 patients were considered nonadherent to their TKI treatment.  
To date three studies have been published and one is submitted (Kekäle et al. 2014, 
2015 and 2016). First published study evaluated CML patients’ adherence to TKIs 
compared to adherence that was estimated by their physicians (Kekäle et al. 2014). It 
also assessed how patients’ knowledge of the disease and its treatment affect adherence. 
Second published study assessed patient-reported adverse drug reactions and their 
influence on adherence and the quality of life (Kekäle et al. 2015). Third published 
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study was an intervention study that evaluated the influence of individualized patient 
education on CML patients’ adherence to TKIs (Kekäle 2016). In this master’s thesis, 
the focus is on the 18 patients that were found to be nonadherent and the purpose of the 
study is to understand the underlying reasons for their poor adherence. 
 
 
7 OBJECTIVES 
 
The aim of this study was to assess the factors related to poor adherence within Finnish 
chronic myeloid leukemia (CML) patients taking oral tyrosine kinase inhibitor (TKI) 
medication for more than six months. The main focus in this study is in the group of 
patients with low adherence based on the MMAS-8 score. 
 
Specific objectives were to assess: 
1) Distribution of answers on MMAS-8 scale 
2) Comparison of the patient characteristics of low and high adherence group 
3) Do patients’ other conditions and medications influence on adherence? 
4) What kind of ADRs occur within the low adherence group compared to high 
adherence group and to ADRs reported on Summary of Product Characteristics 
5) Is there a correlation between perceived experiences of ADRs and poor 
adherence to TKIs? 
6) How the treatment for CML has been provided and organized by the hospitals? 
7) What kind of reasons for poor adherence can be found in the theme interviews? 
 
 
8 MATERIALS AND METHODS 
 
8.1 Study population 
 
The study population consisted of Finnish adult chronic myeloid leukemia (CML) 
patients who had been treated with tyrosine kinase inhibitor (TKI) medication (imatinib, 
nilotinib or dasatinib) for more than six months prior to the study baseline. Seventeen 
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hospitals in Finland treat CML patients and all of these hospitals were contacted for 
participation for the study. Eight hospitals agreed to participate. The participating 
hospitals were the Hospital District of Helsinki and Uusimaa (HUS), South Karelia 
Central Hospital (EKKS), Tampere University Hospital (TAYS), Turku University 
Hospital (TYKS), Mikkeli Central Hospital (MKS), Länsi-Pohja’s Central Hospital 
(LPKS), Satakunta Central Hospital (SatKS) and Oulu University Hospital (OYS). A 
total of 120 CML patients were contacted from these hospitals by their physicians 
during the spring 2012. Of the patients contacted 86 agreed to enrol in the study, 27 
declined to participate and 7 dropped out of the study later on because of the second 
thoughts or deterioration of the general condition.  
 
Ethics committees from the participating hospitals (HUCH, TYKS, TaYS, MKS and 
STK) approved the study protocol. All the patients that enrolled to the study provided a 
written consent. 
 
8.2 Data collection 
 
At the beginning of the study, all the 86 patients were interviewed by the main 
investigator Kekäle. Interviews were conducted individually face-to-face, using a 
structured interview form. The following patient information was obtained: patient’s 
demographic data, information regarding the diagnosis and TKI treatment, patient-
reported ADRs, comorbidities and use of other medications as well as number of 
contacts with physician(s) and nurses. Knowledge of CML and TKI treatment was 
assessed with a specific five-item questionnaire (Kekäle et al. 2014, Appendix 2). The 
symptoms’ influence on patient’s daily quality of life (QoL) was also measured (Kekäle 
et al. 2015). 
 
The interviews were recorded into audiotape and transcribed verbatim by a professional 
transcriber. In four cases, the recording failed and patients were followed-up with the 
phone interview. Phone interviews were not recorded; instead notes were taken by 
writing down the key points. 
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8.2.1 Morisky Medication Adherence 8-Item Scale questionnaire 
 
At the beginning of the interviews, patients’ adherence was measured using Morisky’s 
8-item Medication Adherence Scale (MMAS-8) (Morisky et al. 2008, Appendix 1). 
Prior using the instrument it was translated from English into Finnish, as this was the 
first time that MMAS-8 was used in Finnish population (Kekäle et al. 2014). 
 
Based on the patients’ score on MMAS-8, patients were divided into three groups. 
Patients with the score of 8 on the scale were identified as high adherent, patients with 
the score of 6 to <8 as medium adherers and patients with the score of <6 as low 
adherers. In this Master’s Thesis the main focus is on the low adherence group (Figure 
4). 
 
 
Figure 4. CML patients divided into three adherence groups based on the score in 
Morisky Medication Adherence 8-Item Scale (MMAS-8). 
 
 
8.2.2 Theme interviews 
 
Based on the MMAS results, the investigator conducted semi-structured theme 
interviews for the patients regarding their experiences and perception of CML and its 
treatment and adherence behaviour to their TKI medication. A semi-structured 
interview method is commonly used in qualitative research (Mason J. 2004). While a 
structured interview has specific questions that are gone through the same way with 
everyone, a semi-structured interview is more flexible allowing responses to develop 
CML Patients  MMAS-8 
High adherence  
patients 
8 
Medium adherence 
6-<8 
Low adherence  
<6 
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into an undetermined direction. It can be seen as an interaction between an interviewer 
and an interviewee, where both have an active role, not just an interviewee in providing 
answers. A researcher can use different approaches with different interviewees and this 
might result that new, unexpected themes or ideas can arise by participants.  A semi-
structured interview can use key themes as structures, which are covered during the 
interview. 
 
Interview consisted of a framework of six different themes. The first theme included 
how patients were diagnosed with CML, their experiences and thoughts after being 
diagnosed and how they received information about CML and its treatment. The second 
theme covered patients’ knowledge of CML, and the TKI medication they were taking. 
The third theme consisted of patients’ experienced ADRs and how the treatment 
affected their daily life. The fourth theme covered issues regarding patients’ 
nonadherence to their medication, including unintentional and intentional 
nonadherence, the consequences of nonadherence, and what kind of wishes patients had 
regarding their treatment. The fifth theme consisted of healthcare providers (HCPs) 
impact on the patients’ medication adherence and what kind of expectations patients 
had of their HCPs. The sixth theme covered the strategies patients used in medication-
taking.  
 
8.3 Data analysis 
 
In this study both quantitative and qualitative methods were used. The statistical 
analyses were performed using Microsoft Excel and IBM SPSS Statistics, version 21.0. 
The quantitative variables were presented with mean, SD and percentages. Non-
parametric statistical tests were used because the data was not normally distributed. 
Tests used for categorical data were Pearson’s chi-square  (gender, employment status 
and usually the same doctor) and Fisher’s Exact Test (marital status, number of TKI 
doses, and use of a dosette). Mann Whitney U test was used for continuous parameters 
(Age, age at diagnosis, time from diagnosis, the number of doctor’s visits during the last 
12 months, the number of comorbidities, the number of other medications and 
knowledge total score) and Spearman’s rho for experienced ADRs. 
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The transcribed theme interviews were analyzed using thematic analysis (Hämeen-
Anttila and Katajavuori 2008, a). Both inductive and deductive approaches were used 
(Kylmä and Juvakka 2007). An inductive reasoning starts with single observations that 
are grouped into a broader category. A deductive reasoning starts with a theory and 
moves towards single observations. In this study, the themes used in the semi-structured 
interview provided a framework for the analysis using deductive approach. Moreover, 
the inductive approach provided the possibility to analyze data without any expectations 
or presumptions.  
 
First step was to become familiar with the data by reading the transcript several times 
and making notes for ideas (Hämeen-Anttila et Katajavuori 2008a). The data was 
systematically gone through and the important and interesting features were identified 
and encoded. The codes were then grouped into potential themes, subcategories, so that 
all relevant and data were included and the themes were compared to themes used in the 
semi-structured interviews. The themes and number of the themes were not 
predetermined. Finally, the themes were organized into broader categories. To enhance 
reliability, a second investigator (Kekäle) who had conducted the interviews, encoded 
independently a proportion of transcripts, and codes and themes were then compared 
and discussed between two of us to make sure they were consistent. 
 
All the quotations from the patient interviews that were used as examples in qualitative 
analysis, were translated from Finnish into English by me. 
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9 RESULTS OF QUANTITATIVE ANALYSIS 
 
9.1 Background information of the study patients 
 
9.1.1 Patient characteristics 
 
Sociodemographic factors for the patients who participated in the study are listed in a 
Table 9. Patients who scored < 6 points on MMAS are referred to as “low adherence 
patients” or “nonadherent patients” and patients who scored full marks, the maximum 8 
points, are referred to as “high adherence patients” or “adherent patients”. Of the 
patients (n=86) 21% (n=18) were considered nonadherent and 23% (n=20) adherent to 
their TKI medication. The ratio of men to women was roughly the same among the 
nonadherent patients compared with high adherence patients and with the total group of 
the patients. The average age of adherent patients was 61.5 years, which was seven 
years higher than the average age of nonadherent patients (54.3 years). The majority of 
the patients in all patient groups were diagnosed with CML 1-5 years ago. There were 
no statistically significant differences between different patient groups in regards to age, 
gender, time from diagnosis, marital status, education level or employment status. Over 
half of the nonadherent patients were treated in the Hospital District of Helsinki and 
Uusimaa (HUS), which is the country’s largest hospital district.  
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Table 9. Patient characteristics 
Variables 
 
Low adherence 
patients (n=18) 
MMAS score < 6 
High adherence 
patients (n=20) 
MMAS score 8 
All the 
patients  
(n=86) 
p 
Gender, n (%)  
Male 
Female 
 
10 (55.6) 
8 (44.4) 
 
11 (55.0) 
9 (45.0) 
 
45 (52.3) 
41 (47.7) 
 
0.9731 
 
Age (years), n (%) 
≤ 34 
35-44 
45-54 
55-64 
65-74 
≥ 75 
Mean (SD) 
Range 
 
2 (11.1) 
0 (0.0) 
8 (44.5) 
3 (16.6.) 
4 (22.2) 
1 (5.6) 
54.3 (14.1) 
25-82 
 
0 (0.0) 
0 (0.0) 
5 (25.0) 
8 (40) 
5 (25) 
2 (10) 
61.5 (9.3) 
46-82  
 
3 (3.5) 
9 (10.5) 
24 (27.9) 
23 (26.7) 
20 (23.3) 
7 (8.1) 
57.8 (12.1) 
25-83 
 
0.0793 
Age at diagnosis (years) 
Mean (SD) 
Range 
 
49.6 (15.1) 
19-72 
 
57.5 (10.6) 
43-79 
 
52.7 (12.3) 
19-79 
 
0.1323 
Time from diagnosis 
(years) 
≤ 0.9 
1-5 
6-10 
≥ 11 
Mean (SD) 
Range 
 
 
1 
12 
3 
2 
4.8 (3.9) 
0.8-15 
 
 
1 
13 
5 
1 
4.0 (3.2) 
0.5-11 
 
 
7 
43 
27 
9 
5.1 (3.7) 
0.5-15 
 
 
0.5583 
Marital status, n (%) 
In relationship 
Divorced/ widow/ 
Single 
 
13 (72.2) 
5 (27.7) 
 
19 (95.0) 
1 (5.0) 
 
 
70 (81.4) 
24 (11.6) 
 
 
0.1702 
Education, n (%) 
Basic 
Upper secondary 
University 
 
5 (27.8) 
11 (61.1) 
2 (11.1) 
 
7 (35.0) 
10 (50.0) 
3 (15.0) 
 
25 (29.1) 
52 (60.5) 
9 (10.5) 
 
1.0002 
Employment status n (%) 
At work 
Unemployed/ 
Retired/ student 
 
 
12 (66.7) 
6 (33.3) 
 
 
8 (40.0) 
12 (60.0) 
 
 
45 (52.3) 
41 (47.7) 
 
 
1.0001 
Hospital, n (%) 
HUS 
EKKS 
TAYS 
TYKS 
MKS 
LPKS 
SatKS 
OYS 
 
11 (61.1) 
0 (0.0) 
3 (16.7) 
2 (11.1) 
0 (0.0) 
0 (0.0) 
1 (5.6) 
1 (5.6) 
 
5 (25.0) 
1 (5.0) 
4 (20.0) 
6 (30.0) 
0 (0.0) 
1 (5.0) 
1 (5.0) 
2 (10.0) 
 
32 (37.2) 
7 (8.1) 
16 (18.6) 
17 (19.8) 
2 (2.3) 
3 (3.5) 
4 (4.7) 
5 (5.8) 
 
N/A 
1) Pearson’s chi-square, 2) Fisher’s Exact Test, 3) Mann Whitney U test; N/A = Not applicable 
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9.1.2 Clinical characteristics 
 
Comorbidities and patients’ other medications are listed in table 10. Adherent patients 
had twice as many comorbidities as nonadherent patients and in average three times 
more other medications compared to low adherence patients. This did not include 
vitamins and other supplements. There was a strong correlation between MMAS class 
and number of other medications and a significant correlation was found between 
MMAS class and number of other medications. 
 
Table 10. Comorbidities and concomitant medications 
 Low 
adherence 
patients (n=18) 
High 
adherence 
patients (n=20) 
All the patients 
(n=86) 
P 
Comorbidities, n (%) 
x Hypertension 
x Heart disease 
x High cholesterol 
x Diabetes 
x Musculoskeletal 
disorders 
x Gastrointestinal 
disorders 
x Depression 
x Other cancers 
x Other diseases 
Mean (SD) 
Range 
18 
4 (22.2) 
3 (16.7) 
1 (5.6) 
1 (5.6) 
1 (5.6) 
 
1 (5.6) 
 
2 911.1) 
1 (5.6) 
4 (22.2) 
1.0 (0.9) 
0-3 
44 
10 (50.0) 
4 (20.0) 
4 (20.0) 
2 (10.0) 
5 (25.0) 
 
3 (15.0) 
 
1 (5.0) 
6 (30.0) 
9 (45.0) 
2.2 (1.4) 
0-4 
140 
29 (33.7) 
13 (15.1) 
14 (16.3) 
9 (10.5) 
14 (16.3) 
 
7 (8.1) 
 
3 (3.5) 
18 (20.9) 
33 (38.4) 
1.6 (1.5) 
0-8 
0.0093 
Concomitant medications 
Mean (SD) 
Range 
19 
1.1 (1.1) 
0-3 
71 
3.6 (2.5) 
0-8 
184 
2.1 (2.4) 
0-10 
0.0023 
3) Mann Whitney U test  
 
TKI-medication related factors are listed in table 11. Patients participating in the study 
were taking one of three TKIs. The majority of the patients were treated with imatinib. 
There were no correlations between MMAS class and TKI-medication, line, doses taken 
per day, usually the same doctor, the number of doctor’s visits, the dosette or 
knowledge total score. Patients’ knowledge was poor in all patient groups. 
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Table 11. Treatment and Clinical Characteristics of the CML Patients 
Variables Low 
adherence 
patients  
(n=18) 
High 
adherence 
patents  
(n=20) 
All the 
patients  
(n=86) 
P 
TKI-medication, n (%) 
     Imatinib 
     Nilotinib 
     Dasatinib 
Line 
     First 
     Second 
     Third 
     Fourth 
Doses per day 
     One 
     Two 
Usually same doctor 
     Yes 
     No 
Number of doctor’s 
visits during the last 12 
months 
     Mean (SD) 
     Range 
Dosette 
     Yes 
     No 
Knowledge total score 
0 
1 
2 
3 
4 
5 
 
11 (61.1) 
4 (22.2) 
3 (16.7) 
 
9 (50.0) 
8 (44.4) 
0 (0.0) 
1 (5.6) 
 
14 (77.8) 
4 (22.2) 
 
12 (66.7) 
6 (33.3) 
 
 
 
2.3 (2.7) 
0-12 
 
6 (33.3) 
12 (66.7) 
 
15 (83.3) 
2 (11.1) 
1 (5.5) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
16 (80.0) 
1 (5.0) 
3 (15.0) 
 
12 (60.0) 
5 (25.0) 
3 (15.0) 
0 (0.0) 
 
17 (85.0) 
3 (15) 
 
15 (75.0) 
5 (25.0) 
 
 
 
2.15 (1.3) 
0-4 
 
2 (10.0) 
18 (90.0) 
 
13 (65.0) 
4 (20.0) 
2 (10.0) 
0 (0.0) 
0 (0.0) 
1 (5.0) 
 
67 (77.9) 
10 (11.6) 
9 (10.5) 
 
47 (54.7) 
25 (29.1) 
13 (15.1) 
1 (1.2) 
 
72 (83.7) 
14 (16.3) 
 
58 (67.4) 
28 (32.6) 
 
 
 
2.2 (1.8) 
0-12 
 
17 (19.8) 
69 (80.2) 
 
28 (32.6) 
30 (34.9) 
15 (17.4) 
7 (8.1) 
4 (4.7) 
2 (2.3) 
 
0.5822 
 
0.1712 
 
 
0.5722 
 
 
0.5721 
 
 
0.5063 
 
 
0.0822 
 
0.1913 
1) Pearson’s chi-square, 2) Fisher’s Exact Test, 3) Mann Whitney U test  
 
9.2  Adverse drug reactions of the TKI treatment 
 
Adverse drug reactions (ADRs) were common within all patients group; 89% of low 
adherence patients and all of the high adherence patients reported of having experienced 
at least one or more ADRs as listed in table 12. There was no correlation between 
experienced ADRs and adherence to TKIs. 
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Table 12. The number of patient-reported ADRs of the TKI treatment 
Variables 
 
Low 
adherence  
patients  
(n=18) 
High 
adherence 
patients  
(n=20) 
All the 
patients 
(n=86)  
P 
Number of 
ADRs, n (%) 
0 
1-5 
6-10 
≥ 11 
Mean (SD) 
Median 
Range 
 
 
2 (11.1) 
4 (22.2) 
11 (61.1) 
1 (5.6) 
6.0 (3.4) 
6.5 
0-13 
 
 
0 (0.0) 
8 (40.0) 
10 (50.0) 
2 (10.0) 
6.5 (3.2) 
7.0 
2-15 
 
 
3 (3.5) 
30 (34.9) 
45 (52) 
8 (9) 
6.4 (3.3) 
6.5 
0-15 
 
 
0.7704 
 
4) Spearman’s rho  
 
Both nonadherent and adherent patients reported a number of different ADRs, which 
are shown in Figure 5. Adherent patients had more ADRs on average compared with 
low adherence patients. Over half of the patients in both groups reported having 
experienced muscle pain and cramping, fatigue and swelling of hands, legs, feet or 
around eyes. The patient reported ADRs were consistent with the ADRs listed in 
Summary of product characteristics of TKIs in question (Table 4) but the incidence was 
higher. Aside from one ADR, the incidence of each reported ADRs in both groups was 
10% or higher. 
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Figure 5. Percentage of the non-hematologic ADRs experienced by low and high 
adherence patients 
 
 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90%
Vomiting
Forgetfulness
Shortness of breath
Pain
Feeling of being distressed
Bruising
Drowsiness
Lack of apetite
Feeling malaise
Numbness or tingling
Diarrhea
Feeling sad
Disturbed sleep
Dry mouth
Nausea
Rash or skin changes
Swelling of hands, legs or around the eyes
Fatigue
Muscle pain or cramping
Low adherence patients (n=20) High adherence patients (n=18)
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9.3 Distribution of answers on the MMAS-8 scale 
  
Figures 6 and 7 show the percentage (%) distribution of answers to the MMAS-8 
questions of all study patients (n=86) and low adherence patients (n=18). Forgetting 
was the most common reason for missing the dose in both groups; nearly half of all 
patients and 17 out of 18 low adherent patients sometimes forgot to take their 
medications. However, close to 90% of all patients and over 60% of low adherence 
patients said never or rarely having difficulties in remembering to take all of their 
medication(s) (Figure 7). Low adherence patients reported intentional adherence over 
twice as much as all study patients in the questions 2, 3 and 6 addressing intentional 
adherence (Figure 6). Figure 8 shows the percentage distribution of nonadherent 
patients’ answers to MMAS-8 questions by gender. Both males and females reported 
unintentional and intentional adherence. 
 
Figure 6. The percentage (%) distribution of the answers of all study patients (n=86) 
and low adherence patients (n=18) for the MMAS questions 1-7 
0% 20% 40% 60% 80% 100%
7. Feels sometimes hassled about sticking to
the CML treatment plan
6. Has stopped taking the medication(s) when
CML is under the control
5. Did not take the medication(s) yesterday
4. Has forgotten to bring along the
medication(s) when travelling or leaving home
3. Has stopped taking the medication(s) when
feeling worse without telling their doctor
2. Sometimes intentionally misses taking the
medication(s)
1. Sometimes forgets to take the medication(s)
Low adherence patients (n=18) All patients (n=86)
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Figure 7. The percentage (%) distribution of answers of all study patients (n=86) and 
low adherence patients (n=18) for the MMAS question 8, on 5 item Likert scale: How 
often do you have difficulty remembering to take all your medication(s)? 
 
Figure 8. Distribution of nonadherent (MMAS score <6) patients’ answers on MMAS 
questions by gender (n=18). * The item contains 5 item Likert scale (Once in a while, 
Sometimes, Usually, All the time = less than 1 point; included in the figure). 
0% 20% 40% 60% 80% 100%
 All the time
Usually
Sometimes
Once in a while
Never/Rarely
8. How often do you have difficulty remembering to take all your 
medication(s)?  
Low adherence patients (n=18) All patients (n=86)
0% 50% 100%
8. Has difficultiesin remembering to take all the
CML medication(s)*
7.Feels hassled about sticking to the CML
treatment plan
6. Has stopped taking the medication(s) when
CML in under the control
5. Did not take CML medication(s) yesterday
4. Has forgotten to bring along the CML
medication(s) when travelling or leaving home
3. Has stopped taking the CML medication(s)
when feeling worse without telling their doctor
2. Sometimes intentionally misses taking the
CML medication(s)
1. Sometimes forgets to take the CML
medication(s)
Male Female
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10 RESULTS OF QUALITATIVE ANALYSIS 
 
 
Semi-structured theme interviews with nonadherent patients were analyzed and 
included in the qualitative analysis. Figure 9 shows the framework of themes that were 
developed over the course of the thematic analysis. Table 13 (page 60) shows the 
examples of findings of factors related to nonadherence from the qualitative analysis. 
 
 
Figure 9. The framework of themes from the thematic analysis 
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10.1 Diagnosis 
 
Diagnosis of CML was a big shock to the majority of the patients. Diagnosis was an 
incidental finding in twelve patients in the low adherence group (n=18). Five of them 
had no symptoms at a time of diagnosis and they were diagnosed following the routine 
annual doctor’s check up. This is not unusual, as approximately 50% of the patients are 
asymptomatic at the time of diagnosis (Jabbour and Kantarjian 2016). In seven patients, 
CML was discovered over the course of testing for some other condition while 
experiencing symptoms. Six of the patients had symptoms that can indicate CML, 
which led to the diagnosis. Symptoms included sweating, fatigue, tiredness, and 
abdominal discomfort. Diagnosis was given over the phone for six patients. 
 
Patient: ”As a matter of fact I went to show an irritated mole to an occupational health 
clinic. And then I had had some joint pain. Then the nurse remembered that I should get 
blood work done, because it was a long time since I had it done last time, so that’s when 
it [CML] was discovered”. (1-20)  
 
Patient: ”I went to see a doctor because I was extremely tired and exhausted. I could 
barely walk up the stairs. I could hear the heart beat, like even a small little exertion 
made my head to whistle […] And then I was referred to Hyvinkää immediately”(1-18) 
 
10.2 Care provided by the hospitals 
 
10.2.1 Information received about CML 
 
At the time of diagnosis, the primary source of information is usually a physician. Many 
patients knew nothing about CML before the diagnosis and that is why the quality of 
information, when and how it is given, is important for the patient. The information 
patients received about CML and its treatment from the physicians during the time of 
diagnosis varied amongst the patients. Ten patients perceived that they received right 
amount of information about CML and its treatment. Six of the patients did no think 
they got enough information and one patient had received incorrect information.  Some 
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patients expressed that they received too much information too soon. This made them 
feel that the information was difficult to handle. A number of patients mentioned that it 
was important that information received was supporting, encouraging and highlighted 
the facts that CML is a well-studied, chronic disease with good medications available 
and that it can be managed at patient’s home. Some patients mentioned that it was good 
when information was given by a hematologist, who was knowledgeable about CML 
and its treatment. It was important that lay-language was used and that physician was 
present and had time to talk and go facts over. One of the patients liked how doctor 
avoided the word “cancer” and referred instead of a serious but treatable chronic 
condition. One patient even pointed out that the doctor had been understated the 
seriousness of CML by stating it is not as bad as it sounds.  
 
Interviewer: “Do you think that you got enough information once the diagnosis was 
confirmed? 
Patient: “Yes, once I got to [talk] with actual doctors, who I think were able to explain 
it well, so after that of course I got a better idea of the nature of the disease.” (1-9) 
 
Interviewer: “Do you think that you were given enough information here? 
Patient: “Yes, almost too much. I mean, that I couldn’t understand even half of that 
what I was told. I just listened, OK right. I remember asking, the first thing in my mind 
was, am I going to loose my hair, it was so...” (1-32) 
 
Some of the patients had experienced negatively the way information was given. Two 
patients thought that doctors were not knowledgeable enough. One patient stated how 
doctor had read the results straight from the paper and could not answer any of the 
patient’s questions. Another patient was told wrong information about the cancer, which 
was later on corrected. 
 
Interviewer: “Once it became clear that it is [CML] so do you remember if you got 
enough information or what you were told about CML?” 
Patient: ”Well actually not much at that point. The doctor did say that this is treated by 
taking the medications by yourself, that take the prescription to the pharmacy and then 
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home. But I did not get more information at that time. […] It came maybe afterwards, 
that I would have liked to know right away what this thing is. For example, such 
information, that CML, OK, a serious thing, but luckily can be treated, that something 
more detailed, that it’s OK, that there are this and that kind of medications. At that 
moment, when I was discharged [from the hospital] I didn’t get much information.” (1-
18) 
 
Patient: “It was kind of incompetent physician, he told me at that time, that that’s about 
it [it is terminal]. Then next day the same doctor came, and said that he has now 
consulted [another doctor], that actually it won’t necessarily kill right away.” (3-15) 
 
Over half of the patients had searched information from different sources to learn more 
and to understand better CML and its treatment. Ten patients mentioned that they had 
actively searched information about the disease.  Internet was the most used tool; half of 
the patient had used Internet to find out more about CML, the treatment and what kind 
of experiences other CML patients had about the disease. One patient had stopped using 
Internet because the information there was too oppressive while another patient was 
worrying to find out something bad and scary about CML. Other used information 
sources were brochures that were given out from the hospital and the library books. 
Understanding more about the nature of the disease and good treatment outcomes made 
patients feeling relieved and more comfortable. Conversely, a couple of patients did not 
want to learn more about CML or needed more time to be mentally ready to receive 
information. 
 
10.2.2 Follow-up care 
 
A follow-up schedule was planned based on the time from diagnosis and the laboratory 
results. At the beginning of the treatment patients needed to be followed-up more 
frequently ranging from weekly to every 2 or 3 months. A follow-up schedule was then 
extended to 6 months and then to a year based on the treatment response. Laboratory 
results were in most cases given over the phone by the hematologist. Couple patients 
received the information in the form of a letter. During the follow-up appointments, 
48 
 
patients had a chance to discuss more about their health and current condition with their 
physician. However, a few of the patients did not think it was necessary to see a doctor 
every year if the results had been good and steady and CML was under the control. 
 
Interviewer: “ So how is it at the moment, how often do you go to the policlinic?” 
Patient: “Now I’m getting blood work done every three months. And the doctor’s 
appointment I have only once a year. 
Interviewer: “How do you feel, is that adequate?” 
Patient: “Well yes actually, I think I have quite a good picture about this disease and 
the medications, so I don’t think that I need that much any extra talking. Because it 
really won’t make any difference.” (1-18) 
 
10.2.3 Support from health care personnel 
 
The majority of the patients described that they were very happy with their HCPs and 
support provided. Interactions with physicians and other HCPs were important during 
the time of diagnosis and the follow-up appointments. Two thirds of the patients usually 
had the same physician. If physicians changed frequently, it was experienced 
negatively. Both informational as well as emotional support from the physicians and 
other HCPs had a positive impact on the patients. Especially at the beginning, when 
patients were concerned and had questions about the newly diagnosed CML, 
physician’s support was perceived important. Support consisted of discussions with the 
physician about the disease, treatment, treatment goals, side effects and prognosis in an 
encouraging way. It was also important that the physician had time to talk face to face. 
For the patient it was relieving to know that if there were any concerns, they could 
always contact their HCP and get help. 
 
Patient: “When I visit here [at the clinic], I usually talk with the hematologist. […] And 
the thing is, he provides me with lots of information; that has been a good and 
important thing. […] At the moment, now that I just had a chat with my hematologist 
and so, so now I’m feeling pretty good.” (1-9) 
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Patient: ”Always if there has been something, I have been able to call and get 
examined.” (1-26) 
 
Lack of interaction and information from the physician had a negative impact on 
patients. When doctors changed frequently there was no continuous support. One 
patient was not able to get a hold of the doctor or other HCP when needed in a stressful 
situation. Especially negatively was felt the issue when the newly diagnosed patient had 
many questions and was panicking and there was no one to turn to. Six patients told that 
they had not been informed about the available services such as a psychologist, a social 
worker or other support provided by the hospitals. One patient had tried to contact the 
social worker several times without success. He experienced that he was left alone to 
deal with the feelings. Another patient who participated in the clinical trial perceived 
that appointments were just for tests, lacking mental support from HCPs.  However, 
patients who mentioned that they did not receive any mental support from hospital still 
thought that the care provided was good and taken seriously.  
 
Interviewer: “…you felt that you didn’t get enough that mental support. When you were 
diagnosed, so were you told about the possibility?  
Patient: “No”  
Interviewer: “ So there is absolutely free this, I think it was psychologist or psychiatrist, 
but available for appointments.”  
Patient: “Yes, well at that time it would probably have been really good. I don’t know 
about now, but then. But I think that, when you are participating in clinical trial, so it’s 
mainly just blood tests.” 
 
Patient: ”They [physicians] changed quite often at some point, so that was a bit 
negative thing. […] In a way, I don’t know, I was not informed about any support 
networks or anything like that. But this nurse in question told me that there is this 
medication and now even a second generation one is available and currently more are 
being developed, so in a way there were good people around. And also this 
hematologist, who currently is my doctor, was very good and humane and proficient. In 
that sense I got [support]” (1-18) 
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10.2.4 Patient satisfaction for the treatment 
 
Overall, patients were very satisfied for their physicians and nurses and for the 
treatment received. The quality of care had been excellent and HCPs were considered 
very proficient. Patients described that if there were any concerns they got always taken 
care of and followed-up. None of the patients had any complaints about the patient care 
and treatment. Patients were also very satisfied with the pharmacies and their services. 
Medications had to be ordered in advanced but it worked well and the order came in 
usually on the following day. 
 
Patient: ”…Fortunately we live in Finland, I have experienced excellent competency in 
here. I always remember to tell people that we are in good hands in here.” (1-9) 
 
10.3 Patient’s knowledge 
 
Patients’ knowledge of CML and its treatment have been associated with better 
adherence (Noens et al. 2009; Efficace et al. 2012). In this study, all of the patients had 
fairly poor knowledge about CML and how TKI medications work. None of the patients 
were able to correctly describe what causes CML, eleven patients had vague idea and 
three patients had no idea. The patients were also having difficulties explaining how 
TKI medication works in the body. Eleven of the patients had poor knowledge, three 
could not tell anything and no one was able to correctly explain the mechanism. 
 
Patient: ”I can’t really tell anything else than it’s leukemia. I’m not sure, if I really 
understand, that does it mean that I have some kind of white sick cells who eat red 
blood cells, I don’t know.” (1-17) 
 
Patient: ”Well, there is this kind of cell, a harmful cell that multiplies uncontrollably, 
and then the medication helps in that, or kills that cell. The medication does not 
necessarily cure it, but keeps these harmful cells under control.” (1-29) 
 
Patient: “[Medication] reduces the number of red blood cells.” (1-14) 
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Almost half of the patients understood the importance of taking the medication and 
possible consequences of discontinuation.  Even though they did not exactly know how 
the medication works, many patients knew that if they did not take the medication CML 
could progress to the more advanced state. Three of the patients did not know what 
would happen if they stopped taking their medications. 
 
Patient: ”If you don’t take the medication, then the benefit is wasted, and it affects the 
blood count.” (1-11) 
 
Two patients did not understand the importance of taking the medication regularly. One 
of them claimed that his doctor had told him that it would be fine to be without 
medication for three months. Another patient thought that couple of weeks without 
medication did not matter. When asking how patients would describe what is CML to a 
layperson, couple patients explained how they wanted to highlight the fact that CML is 
a chronic disease. They rather referred CML to a chronic condition such as high blood 
pressure or diabetes, and wanted to avoid using the word ”leukemia” because it sounded 
too serious and could scare other people. 
 
10.4 Social support 
 
Patients’ social support network consisted of spouses, other family members, friends 
and online forums. A third of the patients described that they had a good social support 
network that provided the support they needed. Few patients mentioned that they had no 
one to give mental support they would have needed. One patient described how at first 
people were there for him but after time passed the support diminished. One patient 
described that she did not have the need for support. Social support from family and 
friends provided patients practical and emotional support. Practical support included 
help with household tasks, childcare, medication-management and encouraging resting 
more when feeling worse.  Emotional support consisted of having family and friends 
around and to talk to and having someone who is positive, caring and encouraging. At 
work, co-workers showed their support by waiting until the patient was ready to eat 
after nilotinib dose, so that everyone could go together for a coffee break. 
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Patient: ”He [spouse] makes more often food now and spoils me. […] And after we 
have eaten, he says to me to have some rest on the sofa […] He has been very positive 
and supportive…” (4-7) 
 
Patient: “At the beginning, I visited sometimes online [forums]. There were stories, 
people told what kind of symptoms there have.  That’s where I have looked, but never 
chatted with anybody. I just looked to see, if they had similar problems that I have.” (1-
17) 
 
Patient network group for CML patients is a national network providing information 
and peer support to the CML patients and their loved ones. None of the patients had 
been actively involved in the network. Most patients knew about it but did not feel the 
need to participate. Two patients had not heard about it at all. One patient had attended 
a meeting and three patients were planning to get involved. Two patients mentioned it 
was hard to find information about the meetings or get a hold of the organizer. 
 
10.5 TKI therapy 
 
10.5.1 Adverse drug reactions and their impact on life 
 
The majority of the patients had experienced ADRs while being treated with TKIs. Half 
of the patients described ADRs affecting negatively on the quality of daily life. This 
also affected on their medication-taking behaviour. Particularly fatigue and nausea were 
mentioned by several patients affecting their QoL. Five of the patients had experienced 
fatigue and described how it had impacted on their daily life, preventing them from 
doing some activities they had been able to do prior starting the treatment. One patient 
explained how he used to be in an excellent physical condition and played sports, but 
could no longer do anything these days because he was feeling so weak. Another patient 
described how diminished energy levels made her feel so exhausted that it affected in 
her social life the way that she did not want to leave home or entertain guests. Fatigue 
had affected on ability to work in few patients; one patient was given less physically 
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demanding tasks at the workplace. Another patient had given up of being self-employed 
because it was too challenging to combine long workdays and medication management. 
 
Patient: ”…I have done sports during my whole life, and now I can not do anything. // 
Grip strength. Weakness. […] I was in a very good shape six years ago, I could do 
anything, but now I can’t.” (1-17) 
 
Another common side effect that had a negative effect on the quality of life was nausea. 
One patient described how being on imatinib was mentally challenging because nausea 
was present at all times. For some patients, it caused debilitating condition, disrupting 
their daily life. The patients had tried to take their medication different times of the day 
attempting to find the best time to take it to avoid feeling nauseous.  Many patients took 
their medication with food to prevent or alleviate nausea. One of the patients had given 
up being an entrepreneur, because irregular and long work hours were too hard and 
difficult to combine with medication management. 
 
Patient: ”…This Glivec was so hard, mentally too, because nausea was part of my life 
at that point. Because I tried to take it in the morning, at noon and in the afternoon. 
Then, if I was able to eat a lot, then nausea was not that severe. But still I was nauseous 
all the time.  So it could also be that there is this mental aspect, that when you take the 
medications and then you feel that you become nauseous again… ” (1-9) 
 
Patient: “In the mornings, always two hours following the medication-taking, I became 
really nauseous. I couldn’t really do anything because all I could do was to focus on 
that feeling [of nausea]. (1-29) 
 
Patient: “Earlier I became nauseous when I took it in the morning. […] [But now I take 
it] before going to bed, so then if I get nausea, it comes during the night and I won’t 
notice that” (1-26) 
 
Patients who were treated with nilotinib had to plan their medication-taking around 
daily schedules and meals. Nilotinib has to be taken into an empty stomach, one hour 
54 
 
before or 2 hours after food. This was challenging at times, when a schedule was 
irregular or when travelling. Some patients described how it affected their social life 
and work balance.  
 
Interviewer: “You mentioned that the timing with the meal schedule is something that 
has required some planning, so that then it has become a routine?” 
Patient: “Yes, if you want to be conscientious, so it’s exactly like that, that when you get 
off from work, and are starving, and then you are supposed to take the medication and 
wait. Well, I guess that one hour is kind of OK, but then if you are travelling abroad, 
you take the medication and then you have to wait again before going for the hotel’s 
breakfast. It’s these kind of things. […] It’s not a big problem, but still always a little bit 
in your mind. A minor inconvenience I would say.”  (1-18) 
 
Living with CML can have physical, mental and social impact on patients’ life. Some of 
the patients described how CML had impacted on their mental health, the quality of life 
and ability to enjoy life. Few of the patients suffered depression and felt that 
considering CML as a chronic disease had a negative impact their life. They were 
hoping they could get cured. One young patient felt how all the constant pains she was 
experiencing affected on her quality of life and mood. Another patient had given up a 
dream to live in another country because of CML.  
 
Patient: ”…And then you try to think that no-one at the age of 25 should have, all the 
pain and it’s hurting everywhere, so that’s not normal if you really think about it. […] 
Well, yes it makes you think in a way, that there are diseases that can be totally cured, 
that not that I’m thinking about it all the time, but it sometimes really gets to me that I 
have to take them [medications], that why it just cannot be removed from my body.” (1-
32) 
 
Interviewer: “…There are few symptoms, that could be, that because of the medication 
or the disease, so have you experienced, how these affect on your general functioning or 
mood, do they?” 
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Patient: ”…Well yes I think that it might affect, that it is the morning thing, that it is 
hard to get myself up moving. […] That it’s sometimes that I don’t feel like doing 
anything. (1-11) 
 
Not all patients had negative feelings about CML and its treatment. Few of patients did 
not feel bothered about sticking to a treatment plan and felt that medication was easy to 
take. One patient who had previously been taking injectable interferon was happy after 
it was switched to imatinib.  
 
Patient who had been on interferon: “In a way, it was a happy day, when I got this 
Glivec.” (3-15) 
 
10.5.2  Unintentional and intentional non-adherence 
 
All nonadherent patients reported unintentional nonadherence and two-thirds intentional 
adherence. In few cases patients reported intentional adherence as a consequence of 
unintentional reason. The most common reason for unintentional adherence was 
forgetting to take the medications (n=12). Most common reasons for forgetting were 
simple forgetting and forgetting as a result of departing from usual routine. Changes in 
a daily schedule caused patients to forget to take the daily dose, such as changes in a 
morning routine or if they came home later than usually. Sometime a patient missed the 
dose after felling asleep in a cough. 
 
Patient: ”I just simply sometimes forget but not very often. The only times that I really 
might forget them is when I go to the bed really early. […] And then I might miss 
evening meal. […] Those are the only times, because I always remember the 
medications when I have something to eat.” (1-9) 
 
Patient: ”…Just occasionally, if I have a little unusual morning. Usually I take it in the 
morning, so then if I’m in a rush or leaving at unusual time, I might be already sitting in 
a car and remember, that oh no, I forgot it.“ (1-29) 
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A common reason for forgetting was travelling. For example, one patient who 
frequently travelled for work sometimes forgot to take the medications with him. 
Another patient described how it was difficult to remember to take the medication after 
moving into a new home, where medications were stored in a new place. A patient who 
uses a weekly dosette sometimes forgot to fill it, which resulted in forgetting to take the 
medication. Another patient had stopped using a pill organizer because it did not help in 
remembering. One of the patients felt it was generally stressful to try to remember to 
take the medication. Some patients mentioned that they were frequently having 
difficulties remembering to take the medication. 
 
Intentional adherence was most commonly related to ADRs of the TKI medication.  
One patient described that reason for not taking the medication was not because of 
forgetting but rather because of the adverse effects. Two patients had skipped the dose 
during holidays. One patient told that during the holidays she does not want to think 
about CML or routines at all and therefor was not taking the medications when on 
holiday. Another patient did not want to take the daily dose to avoid ADRs during 
Christmas and other holidays or when visiting. Sometimes a patient may face some 
challenges in medication-taking that are beyond their control. One patient was unable to 
take the medication when he had a bad stomach flu and could not take anything by 
mouth. Another patient had to discontinue imatinib during her pregnancy. 
 
Interviewer: “…You told that it has happened three times that you have not taken the 
medications for some other reason than forgetting, so in what kind of situations this has 
happened? 
Patient: “Christmas Eve and now May Day Eve. We were visiting, so in that kind of 
situations. […] Once I missed it when I had awful stomach flu, couple weeks ago, so 
once because of sickness. […] At that time I could not eat anything.” (1-20) 
 
Three patients reported the combination of unintentional and intentional adherence. 
Two of the patients described that sometimes they would remember their medication 
when they were already in bed and that in such case they decided to skip the dose. One 
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patient said that if she misses the daily medication taking time by over 2 - 3 hours then 
she does not take the medication at all. 
 
Patient: ”…And then I might remember [the medication] in the evening, when I’m 
already in the bed. And then if I haven’t eaten anything, so I’m not going to go upstairs 
to eat anymore, because there is no way I would take them if I haven’t had a meal. I 
have done that couple times before, and then I got an awful head ache and felt 
nauseous, and it takes an hour to get over it, so that’s why I just don’t. My husband 
doesn’t like it, but then I don’t always tell him. […] Yes, I do get it that you have to take 
them, so I don’t skip them very often, but in the situation like that, I skip them.” (1-32) 
 
10.5.3 Patients’ beliefs 
 
Patients’ beliefs about the medication can have an impact on their adherence. A patient 
might think that decreasing the dose or stop taking the medication has little or no impact 
on the clinical outcome. Two patients admitted that they had changed the dose or 
stopped taking medication without talking to the doctor.. One patient had decreased the 
dose from four to two tablets because of the GI related side effects he was experiencing. 
He was aware that at the time CML was under the control. Also beliefs about 
medications in general can have an impact on patient’s attitude toward the treatment.  
 
Patient: “All the medications are toxic in a way, even though they treat this.” (1-26)  
 
10.5.4  Motivation and reasons for being adherent 
 
Understanding the importance of TKI treatment and the nature of disease progression 
were most common reasons that motivated patients to take their medications. The 
patients described how CML is a serious condition but there are good medications that 
can prevent disease from progressing and enable them to keep fit for work. The 
effectiveness of TKI medication was considered as a motivating factor for many 
patients.  Some patients mentioned that there were no negative factors in taking 
medication. Patients described the following factors about the medication: it is easy to 
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take, a pill form, does not need to be injected and does not limit the daily life. They 
thought that being on the medication has not changed their life anyhow. Taking the 
medication was not perceived as inconvenient.  
 
Interviewer: “So have you been happy with it [the medication]? 
Patient: ”Yes, it’s nothing, it’s not that difficult, just swallow it and that’s it. It’s really 
easy.”  (1-17) 
 
 For one patient, the high price of medication motivated to take it. Another patient 
described how he was diagnosed eleven years ago and how the life expectancy had 
dramatically changed and thus he has started to trust the treatment. A physician can play 
significant role motivating patients to take the medication. In one case, the patient liked 
the way his hematologist always sets “a goal” for the next laboratory test results. A 
medication change from other type of treatment for a new one can also motivate 
patients, like in the case when the patient was happy after his daily injectable interferon 
was changed to imatinib. 
 
10.5.5 Strategies used in medication management 
 
Most patients had some kind of strategy in medication-taking. Used strategies were 
either to help in remembering to take the daily medications or making medication-
taking easier and more practical. Many patients perceived it challenging to incorporate 
medication taking into the daily schedule. Imatinib should be taken with food to avoid 
ADRs such as nausea and nilotinib has to be taken in to an empty stomach at least one 
hour before a meal.  
 
Patient: “Well actually fasting is quite troublesome, it really is. Not always, but every 
now and then, it depends, like if you are somewhere away. And like we were just on a 
business trip, so then it requires lots of planning”. (1-20) 
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Interviewer: “Some people feel that it is a bit difficult, if you have to take the 
medication every day, and especially if you have to take it multiple times per day, so do 
you feel that is it troublesome to use this medication?” 
Patient: “Well yes, it is. Just then, in the morning when you take it, when you have some 
water, that damn I wish I could get away from this [CML].” (1-11) 
 
The most common strategy in medication taking was to take the medication routinely at 
the same time every day. Having a routine helped patients to remember to take their 
medications in time. Some patients who were also taking other medications took them 
always at the same time together with their TKI-medication. In some cases patients kept 
the medications in a specific place, where it was easy to remember to take. The patients 
whose daily schedules were irregular had developed some useful strategies for making 
the management of their medication regimen easier. One patient kept part of his 
medications in his car so that they were always readily available whenever he finished 
working. Another patient had placed some of his medications in a small bag inside his 
wallet, which he always carried on him. This way he always had the medications with 
him and would not miss the dose. Tools that were used in helping medication 
management were a weekly dosette and a phone reminder. One patient was using both 
methods. Some patients had spouses who helped and reminded them to take the 
medications. One patient did recalculations to make sure he had not missed any doses. 
Another patient went to the pharmacy every month to get filled a one-month supply of 
his medication. 
 
Patient: ”…I had an idea, that I throw a little bag in my wallet, the kind of that can be 
compressed and I put always approximately one week supply in it. And I have my 
medications in it with me. That’s why I haven’t forgot them. (1-9) 
 
Patient: ”…I take it [medication] usually in the morning at work around 8-8:30. But on 
the weekend at home I take it at 7 am…” (1-20) 
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Table 13. Factors related to nonadherence –examples from the analysis 
Themes Sub-themes Quotations 
Diagnosis Incidental finding 
 
 
Symptoms led to 
diagnosis 
“It was a semi-annual check-up, I went to see a doctor to Malmi. […] And soon after that the doctor called me and said that I 
have to get immediately here [Meilahti Hospital] that they have an available space ready for me.” (1-11) 
 
“It started from the back pain, It was so bad that I had to be taken to the hospital by an ambulance. Then for some reason the 
doctor ordered these tests. I didn’t know anything about it but I had been wondering, for couple of weeks, that why am I sweating 
so much all the time, excessively, sweat was running. I was thinking that something is not right that it must be something, 
because I have never been sweating like that before. I told about this at the hospital and they said that it’a one of the typical 
symptoms.” (1-17) 
Information received 
about CML 
Adequate amount of 
information 
 
 
 
 
 
 
 
Too much information 
too soon 
 
Not enough 
information 
”Well he told me that what this disease is and that there are 3 different medications that can be used to treat this.  And then [the 
physician] avoided the word leukemia, told that this is similar and serious disease, but now there is a medication for it, so no 
reason to get really scared, that you can survive and have still years to live. […] There was a really good service in there. They 
came right away to talk, doctor came right next to me and we talked” (1-11) 
 
Patient: ”They didn’t talk anything about what causes the disease, they didn’t know about it. But the doctor said that you have 
won in a lottery, that it is the kind of [disease], that the medications for it has been developed ten years ago. That when you take 
these, you will survive.” (4-7) 
 
”I suppose I was told about everything that there is to tell and what they know. The initial shock, what is coming, so then you 
might not be able to hear everything that they say.” (1-29) 
 
* The patient didn’t receive much information from the doctor, has searched information by herself. She didn’t receive any 
written information, was not ready for more information. (8-5) 
Follow-up care Follow-up 
appointments 
 
 
Lab control 
“Now I have had appointment every 3 months but now the next one is in 6 months. So now they [appointments] are less 
frequently, because it looks like the medication is working well (1-9) 
 
“…I have the lab test every 3 months, so doctor then always calls about the results. […] I think that’s good, that I don’t have to 
go to see a doctor to hear about the results” (1-22) 
Support from health 
care personnel 
Support received 
 
 
 
 
 
 
Did not receive support 
“…In a way good people came to me. And also this hematologist, who still currently takes care of me, was really good and 
humane and proficient. In that sense I got [support].” (1-18) 
 
“When I visit here [at the clinic], I usually talk with the hematologist. […] And the thing is, he provides me lots of information; 
that has been a good and important thing. […] At the moment, now that I just had a chat with my hematologist and so, so now 
I’m feeling pretty good.” (1-9) 
 
* The patient did not get support from the hospital, although otherwise has been received good care. He was given a phone 
number for social workers but despite multiple phone calls, could not get a hold of them. (7-3) 
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Satisfaction with care Satisfied with the care. ”I think it [care] has been good. And the way that everything is carefully checked and followed-up. It’s very good indeed. I am 
very satisfied with it.” (4-7)  
Patient knowledge Poor knowledge of 
CML 
 
Poor knowledge of 
TKI 
 
 
Understanding the 
importance of the 
treatment 
”I can’t really tell anything else than it’s a leukemia. I’m not sure, if I really understand, that does it mean that I have some kind 
of white sick cells who eat red blood cells, I don’t know.” (1-17) 
 
”Well it likely kills these cells, good and bad ones, probably.” (1-32) 
 
”I assume that it controls the growth, but I don’t know how.” (3-15) 
 
”If you don’t take the medication, it can transform to an acute leukemia.” (1-14) 
Social support Support from family 
 
 
Support network/ 
friends 
 
Support from co-
workers 
 
Pear support 
”He [spouse] makes more often food now and spoils me. […] And after we have eaten, he says to me to have some rest on the 
sofa […] He has been very positive and supportive…” (4-7) 
 
Interviewer: “Do you think that have you had a social network or friends or support that you have been able to talk with about 
these things?” Patient: “Yes.” 
 
“My co-workers are very understanding [regarding fasting before taking nilotinib] and then everyone waits that we all go for a 
coffee together.” (1-20) 
 
* The patient has been chatting with online support group. (3-13) 
ADRs and their impact 
on life 
Impact on general 
functioning and mood 
 
 
 
Fatigue 
 
 
Work tasks 
 
Social life 
 
Nausea 
 
 
 
 
Depression 
 
Interviewer: “How do you feel, if you think about how these symptoms affect on life, your general functioning, mood, has it 
affected?” Patient: “Yes.” Interviewer: “How about enjoying life?” Patient:”Well, yes a little bit. […]And then you try to think 
that no-one at the age of 25 should have, all the pain and it’s hurting everywhere, so that’s not normal if you really think about 
it.’ (1-32) 
 
”…I have done sports during my whole life, and now I can not do anything. // Grip strength. Weakness. // Six years ago I was in 
a very good shape, I could do anything, but now I can not.” 1-17 
 
* The patient is not in full physical shape. Has not been assigned physical tasks at work. (8-5)  
 
”Yes, it really affects, for the social [life], that I don’t feel like inviting anyone or visit anyone.” (1-20)  
 
”…This Glivec was so hard, mentally too, because nausea was part of my life at that point, because I tried to take it in the 
morning, at noon and in the afternoon. Then, if I was able to eat a lot, then nausea was not that severe. But still I was nauseous 
all the time.  So it could also be that there is this mental aspect, that when you take the medications and then you feel that you 
become nauseous again… ” (1-9) 
 
“…But in some way you get depressed, when you are tired, so that’s what happens and a fear.” (4-7) 
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Muscle cramps “At first I was afraid, because it had happened couple times that my foot started to cramp when I was driving a car. […] That’s 
what I was afraid of at the beginning, that my feet, because then it is hard to control the car.” (1-27) 
Unintentional 
nonadherence 
  
 
 
Forgetting 
 
 
Changes in the daily 
routines 
 
Not at home 
 
 
Forgets to fill the 
dosette 
 
 
Move to a new home 
” I just simply forget sometimes but not very often. The only times that I really might forget them is when I go to the bed really 
early.”(1-9) 
 
” …Just occasionally, if I have a little unusual morning. Usually I take it in the morning, so then if I’m in a rush or leaving at 
unusual time, I might be already sitting in a car and remember that oh no, I forgot it…“ (1-29) 
 
* The patient might miss to take the medication if there are some changes on the schedule and she is somewhere else, and does 
not have any medications on her (8-5) 
 
Interviewer: “Then you have a dosette, you fill it on Monday mornings, and sometimes you have then forgot to fill it and then 
there has been some problems in remembering, or how did it happened? Have you had the dosette from the beginning?” Patient: 
“Yes I have” (1-17) 
 
“Well, it happened, now that we moved. And the medication was placed in another place, and then suddenly I said to my 
husband, that did I took them?” (4-12) 
Intentional 
nonadherence 
 
ADRs 
 
 
Holiday / Visiting 
friends or family 
 
 
Travelling 
 
 
Temporary illness 
 
Pregnancy 
 
Discontinuation 
 
Dose change 
 
Remembers to take the 
medication too late 
 
”…Skipping the medication is not because of forgetting them, but rather because of something else, like the adverse effects…” 
(1-26) 
 
“Christmas Eve and now May Day Eve. We were visiting, so in that kind of situations.” (1-20) 
 
* On holidays the patient doesn’t want to remember the routines  (3-4) 
 
”…Now it just happened, just when we were going to Thailand, and the layover was so long, so then I missed taking it… ” (1-
11) 
 
“Once I couldn’t take it when I had awful stomach flu, couple weeks ago, so once because of illness.” (1-20) 
 
”…And of course during my pregnancy [discontinued the medication].” 1-32 
 
* The patient has discontinued the medication for 2 months without consulting doctor (3-4) 
 
* The patient has changed to dose by himself  (7-3) 
 
 “And then I might remember [medication] in the evening sometime, when I’m already in the bed. And then if I haven’t eaten 
anything so I’m not going to go upstairs to eat anymore, because there is no way I would take them if I haven’t had a meal.“ (1-
32) 
 
* If the patient misses the medication-taking-time by 2-3 hours, then won’t take the medication anymore. (7-3) 
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Motivations and 
reasons for taking 
medication 
Effectiveness of the 
medication 
 
The high price of the 
medication 
 
Easy to take 
 
 
 
Mild ADRs 
“It of course motivates, those effects and when I am given a treatment goal” (1-9) 
 
 
”…It is a doctor’s wish too [to always take the medication], because it is so expensive medication…” (1-11)  
 
 
”…It is not that difficult, just swallow it and that’s it. It is really easy.”  (1-17) 
 
”It has been quite good, small enough pill.” (1-29)   
 
”Adverse effects has been very mild, if there is any. […] But this medication doesn’t really put a strain on me” (1-14)  
Strategies used in 
medication 
management 
 
Routines 
 
 
Keeps medications 
always in the same 
place 
 
Takes together with 
other medication(s) 
 
Takes always with a 
meal 
 
A dosette 
 
Carries small amount 
of medication with 
him/her 
 
Keeps medications in 
a car 
 
Pill counts  
 
Spouse reminds   
 
Phone reminder 
 
Self regulation 
 
”You just have to go in to that place, where you take the medications, you have to make a routine of it. Having a routine is 
important.” (1-9) 
 
”…I put that container on the night table in the evening, and then when I see it, then I remember.” (1-29)  
 
 
 
“I take it always at the same time [with Somac], always exactly at the same time.” (1-9)  
 
 
“…I always remember the medications when I have something to eat”(1-9) 
 
 
” …I have the kind of dosette. […] My wife takes care of it [filling the dosette]” (1-11)  
 
”…I had an idea, that I throw a little bag in my wallet, the kind of that can be compressed and I put always approximately one 
week supply in it. And I have my medications in it with me. That is why I have not forgot them. (1-9) 
 
Interviewer: “And you mentioned that the medications are always with you, that you have the habit that [you have it] in the car, 
you usually take it after work day.” Patient: “Yes.” (1-18) 
 
* The patient does recalculations to make sure that he has taken all the medications (3-4)   
 
”…He takes care of me, and [asks] have you taken the medications. […] Yes he takes care of that [reminding about the 
medications] a lot.” (4-7)  
 
”I have a phone reminder” 1-20 
 
”Well usually, if we are going to a party for instance, or of course if I have time off, so then I take it already in the morning, at 
least so that not at the party. Because you never know if they make you feel sick or give you a head ache or something.” (1-32)  
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Gets one month 
supply of medication 
at a time 
* The patient gets his prescription refilled one month at a time (7-3) 
 
Reasons that make 
medication 
management difficult 
Timing with fasting  
 
 
 
 
Timing with taking the 
medication with a 
meal 
 
Sticking to the daily 
treatment plan 
 
“Yes, if you want to be conscientious, so it’s exactly like that, that when you get off from work, and are starving, and then you 
are supposed to take the medication and wait. Well, I guess that one hour is kind of OK, but then if you are travelling abroad, 
you take the medication and then you have to wait again before going for the hotel’s breakfast. It’s these kind of things. […] It’s 
not a big problem, but still always a little bit in your mind. A minor inconvenience I would say.” (1-18) 
 
“I would say, that Glivec is better to take with a meal, preferably with a large meal. Because if you can take it with a large meal, 
so then it [nausea] is easier to control. But that kind of job, I didn’t really have time to eat barely anything, so that made it more 
difficult. “ (1-9) 
 
Interviewer: “Some people feel, that it is a bit difficult, if you have to take the medication every day, and especially if you have 
to take it multiple times per day, so do you feel that is it troublesome to use this medication?” Patient: “Well yes, it is. Just then, 
in the morning when you take it, when you have some water, that damn I wish I could get away from this [CML].” (1-11) 
*Written notes from the follow-up phone interviews after recording failed
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11 DISCUSSION 
 
The aim of the study was to assess factors related to poor adherence to TKIs in Finnish 
CML patients. The main focus in this study was in the group of patients who were 
classified as low adherent based on the MMAS-8 scale.  
 
11.1 Methodological discussion 
 
11.1.1 Conduct of the study 
 
In this study, both quantitative and qualitative methods were used. Quantitative methods 
were used to compare low and high adherent patients’ sociodemographic and clinical 
characteristics to find out if there were associations between any of these factors and 
adherence. Incidence and the types of ADRs and their impact on adherence were also 
studied. The distribution of answers on MMAS-8 scale provided information about 
intentional and unintentional adherence behaviour.  
 
A qualitative method, thematic analysis, was used to analyze theme-interviews of 
nonadherent patients. Both inductive and deductive approaches were used. The themes 
used in the semi-structured interview provided a framework for the analysis using the 
deductive approach. In addition, the inductive approach was chosen to provide the 
possibility to analyze data without any presumptions or expectations. This would allow 
that something that has not been previously reported from other studies could be 
revealed. Theme interviews were analyzed to explore nonadherent patients’ thoughts, 
experiences, beliefs, knowledge and perceptions about having CML and its treatment 
and how that could contribute to nonadherent behaviour.  
 
This study is part of a larger study and the data for the study was collected in 2012 for a 
doctoral thesis. Part of the study findings has already been published. The data 
collection was carefully designed and consisted of large amount of patient data and 
transcribed interviews.  
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Adherence to TKI treatment in this study was measured using MMAS-8 scale, and to be 
fully adherent patients had to score full marks, 8 points. Patients who scored less than 
six points were classified as nonadherent. Comparing adherence rates with other studies 
is challenging as there are many different methods used to assess adherence. Commonly 
used objective methods are pill count, MPR and MEMS and subjective methods patient 
self-report and physician assessments. All of the methods, including patient self-reports 
such as MMAS-8, have some limitations and disadvantages and measuring adherence 
accurately and reliably is difficult (The World Health Organization 2003). It has been 
suggested that more accurate result would be possible to obtain if two different 
methods, subjective and objective, were combined (Hawkshead and Krousel-Wood 
2007), as some of the studies have done (Darkov et al. 2007; Noens et al 2009). The 
choice of a measure for adherence assessment depends on resources, the convenience of 
the method and what kind of information needs to be obtained (Hawkshead and 
Krousel-Wood 2007).  
 
In this study, the choice of MMAS-8 was reasonable. It was easy and convenient to 
incorporate to the patient interviews and the investigator who carried out the interviews 
was able to obtain the results of the assessment right away at the clinic where the 
interviews took place. In addition to measuring the level of adherence, MMAS-8 
questionnaire provides important information about patients’ medication-taking 
behaviour and barriers they may be facing in their treatment regimen (Morisky et al. 
2008). Questions also reveal information about unintentional and intentional 
nonadherence. Disadvantages of this method are that patients may overestimate their 
adherence, provide answers that they think the interviewer wants to hear or have recall 
issues (Morisky et al. 2008). As the method is subjective on its nature, the answers may 
also depend on patients’ personal characters. For example when asking how often a 
patient has difficulties in remembering to take their medications, for one patient “once a 
week” could mean “often” while for another patient it may mean “rarely”. Another 
problem when comparing results with previous adherence studies is how high and low 
adherence has been defined. For instance, in their study Eliasson et al. (2011) 
considered patients as nonadherent if their MEMS rate was ≤90%. In another study of 
Anderson et al. (2015) patients who took <90% of their dose, measured using MPR, 
67 
 
were classified nonadherent. In these methods, to be considered adherent, patients had 
to score at least 90% rate. While using MMAS-8, patients had to score full marks 
(100%), to be considered as adherent.  
 
Theme-interviews were recorded into audiotape and transcribed verbatim. Transcribed 
theme-interviews were sometimes inconsistent as some of the themes or subjects were 
not covered in all interviews. In few cases the interviewer and a patient had already 
discussed about some of the subjects before the actual recording started, in which case 
the interviewer shortly repeated the unrecorded subjects. This way she was able to bring 
up some of the missed key points during the recording. However, this resulted that some 
information was missing from the transcripts and not all questions were answered the 
way a more structured questionnaire would have. On the other hand, the idea of the 
semi-structured theme-interview is that it is not too carefully structured so that 
something unforeseeable issues could come up. 
 
11.1.2 Validity and reliability 
 
Validity means how well the study method measures what it is supposed to measure 
(Hirsjärvi et al. 2013). Reliability refers to how well the study findings can be repeated, 
and in qualitative analysis how well data analysis can be repeated (Hirsjärvi et al. 2013; 
Hämeen-Anttila et Katajavuori, 2008b). To enhance validity, it is important to carefully 
describe every phase of the study and how it was conducted (Hirsjärvi et al. 2013).  The 
use of triangulation, also known as mixed methods, which combines different study 
methods such as quantitative and qualitative methods, is another way to enhance 
validity. Investigator triangulation means that multiple researchers are participating in 
data collection or data analysis. 
 
The sample size of the study population of 86 CML patients was fairly small to have 
statistical significance in quantitative analysis. However, it was still able to provide 
important information about the patient characteristics and ADRs. In this study, the 
theme-interviews and patient questionnaires were used to provide more comprehensive 
data.  
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The validity of data collection was enhanced by the fact that interviews and measuring 
the patients’ adherence were carried out by the researcher who was not involved in the 
patients’ care, instead of their physician. This way patient could provide more honest 
answers without the fear of being judged by their physician about possible nonadherent 
behaviour. Also, in data collection during the interview, the presence of the researcher 
could improve validity, in case the patient needed clarification for some of the questions 
being asked. As the patient interviews were in Finnish, patient quotes chosen as 
examples for the thesis were translated into English by me. The validity of translation 
could have been improved by having a second translator. 
 
The theme-interviews were transcribed verbatim and this ensures that nothing that 
interviewee said is missed during the data analysis, which can enhance reliability. It 
also provides examples to support the study findings.  In four cases, the recording failed 
and the interviews were completed with the phone interview. Phone interviews were not 
recorded; instead the interviewer took notes and wrote down the key points. This 
weakens the reliability of these interviews, as notes were short summaries of the key 
subjects, not transcriptions of what patients said with their own words. This could result 
that some important factors may have been missing from the data. To enhance the 
reliability of the theme-interview analysis the second researcher, who had performed the 
data collection, coded independently part of the transcripts. After this the codes and the 
themes were compared to make sure they were consistent.  
 
11.2 Results 
 
Importance of good adherence to TKIs in the treatment outcome of CML has been 
showed in several studies (Noens et al 2009; Marin et al 2010). However, a number of 
studies show that nonadherence is a frequent problem among CML patients.  A 
nonadherence rate among study patients was 21%, which is in line with other studies, 
where nonadherence rates among CML patients range from 26% to 47% (Table 8). 
Only one study was found that had a low nonadherence rate of only 3% (Jönsson et al. 
2012).   
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11.2.1 Patient related factors 
 
Patient sociodemographic and clinical characteristics 
 
The key findings propose that patient sociodemographic characteristics do not predict 
adherence, while more concomitant medications and comorbidities were associated with 
high adherence. There was a significant association between higher adherence and 
concomitant medications and comorbidities. High adherence patients had on average 
twice as many comorbidities and three times as many concomitant medications 
compared to low adherent patients. This may sound surprising, as one might think that 
more medications could make medication managing more complex.  However, several 
studies have had similar findings (Noens et al. 2009; Efficace et al. 2012; Anderson et 
al. 2015). It does not appear from the study data if patients already had existing 
conditions when they were diagnosed with CML. When patients have to take more than 
one medication, they may have to be more careful and thorough in managing 
medication-taking. If the other conditions were pre-existing, patients may already have 
integrated the medication-taking routine into their daily life. Patients who have only one 
medication to take may be more prone to slips as it might not feel so bad to miss one 
medication instead of several medications. 
 
Distribution of answers on MMAS-8 
 
The distributions of answers on MMAS-8 scale were somewhat inconsistent. Almost 
90% of the nonadherent patients admitted sometimes forgetting their TKI medication 
and half of the patients felt sometimes hassled about sticking to the treatment plan. 
However, when asking how often they had difficulties in remembering, over 60% 
answered rarely/never. Forgetting is human and it probably happens to everyone at 
some point, even for patients who are motivated and adherent to their treatment. Half of 
the patients admitted sometimes intentionally skipping the dose and based on the theme-
interviews major reason for this is experienced ADRs. Some patients answered that they 
had stopped taking their medication when feeling that CML is under control. A patient 
might believe that once the disease is under control, it is not that serious if they 
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sometimes skip the dose. Eliasson et al (2011) had similar findings in their study; some 
of the patients did not think missing the medication occasionally would affect the 
treatment outcome. 
 
Knowledge and information received 
  
Previous research suggests that good knowledge of the disease and treatment predicts 
better adherence (Noens et al 2009; Jönsson et al. 2011; Efficace et al. 2012). However, 
in this study there was no association; knowledge was not good in either adherence 
groups. To assess their knowledge, patients were asked five questions about CML and 
its treatment. Maximum score for the knowledge test was five points. Most patients in 
both adherence groups scored zero points, and few patients one or two points. Only one 
high adherent patient scored full five points. Despite the poor results in the test, 
nonadherent patients were satisfied with the information received. For the people 
without any educational background in medical field, disease pathophysiology and the 
mechanism of action of TKI can be difficult to understand. This explains why some of 
the patients mentioned that it was important that physician used lay-language. What is 
important though is that many nonadherent patients understood the importance of the 
TKIs in the treatment outcome of CML, even though it was difficult for them to explain 
what happens in their body if they do not take the medication. This could be regarded as 
one of the most important motivational factors to adhere to treatment.  
 
Unintentional and intentional adherence 
 
Patients reported both unintentional and intentional nonadherence. All except one 
patient answered that they sometimes forget to take their medication(s). Half of the 
patients answered that they sometimes intentionally miss taking their medications(s). 
Intentional adherence was more common in women. Forgetting was the most common 
reason for unintentional adherence and avoiding ADRs for intentional adherence. This 
is in line with previous study assessing intentional and unintentional adherence in CML 
patients (Eliasson et al. 2011). Usually forgetting happened as a result of changes in 
daily routines or while not at home. The study findings suggest that even though many 
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patients expressed intentional nonadherence in MMAS-8 assessment, based on the 
interviews most patients were not careless or unconcerned about their TKI treatment. 
Only few patients understated the importance of taking the medication regularly.  
 
Experiencing ADRs is unfortunately part of the daily life for most patients. This 
resulted that patients were adjusting the medication-taking time in case they wanted to 
avoid having ADRs, for example if they were going to a party or during holidays. 
ADRs also led one patient to reduce the dose without telling the doctor. Patients might 
need more information regarding how often is safe to miss an odd dose without 
affecting their treatment response and at what point it can become problematic. This 
way, if needed, they can modify their treatment regimen in case of a special occasion. 
Based on their study Marin et al. (2010) suggested that ≥90% adherence measured using 
MEMS was needed to maintain an adequate response to TKI treatment. 
 
Understanding the importance of the treatment was a motivating factor for patients to be 
adherent. This is something physicians and other HCPs should frequently highlight and 
remind the patients about. Patients who are well informed have been shown to be well 
adherent to their treatment in other study (Jönsson et al. 2012). 
 
11.2.2 Treatment related factors 
 
Adverse drug reactions and their impact on life 
 
Results showed that TKIs causes a wide range of ADRs, impacting the majority of the 
patients. Experienced ADRs were consistent with what have been reported on SPC of 
each TKI-medication. However, there was no association in between patient 
experienced ADRs and nonadherence. Contrary to what would have been expected, 
patients who were high adherent had on average more ADRs compared to low adherent 
patients. While 89% of the low adherent patients had ADRs, all of the high adherence 
patients had ADRs. Muscle pain and cramps, fatigue and swelling of hands, legs or 
around the eyes were most commonly reported ADRs in both groups. The findings are 
in line with three studies, where experienced ADRs were not predicting low adherence 
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(Efficace et al. 2012; Anderson et al. 2015; Kapoor et al. 2015). However, in few other 
studies there was a correlation between experienced ADRs and low adherence (Noens et 
al 2009; Marin et al. 2010; Roosevelt et al. 2012).  
 
Experienced ADRs are a common factor negatively affecting the quality of life and 
contributing intentional nonadherence. In the qualitative analysis a number of patients 
expressed how ADRs, especially fatigue and nausea, had a negative impact on their life. 
Fatigue led patients to have less active lifestyle, limited social life and even resulted 
changes in a job description. Dealing with nausea was mentally challenging, affecting 
many patients’ daily life. Over 20% of the patients admitted that they had stopped 
taking the medication when feeling worse.  
 
One might assume that patients can tolerate better ADRs if their disease is serious. 
However, dealing with ADRs is not easy, especially if a patient does not feel the disease 
itself, when disease does not have any symptoms. Diagnosis was an incidental finding 
for over half of the patients and five of them had no symptoms at all at the time of 
diagnosis. Only six of the nonadherent patients had had CML-related symptoms prior 
the diagnosis. If a patient feels better when not taking the medication, it is 
understandable that ADRs following the medication-taking can be frustrating for the 
patient. On the other hand, some patients might associate ADRs to the effectiveness of 
the medication and tolerate ADRs better for this reason. ADRs are common and most 
patients experience them at some point. Patients should be encouraged to talk to their 
physician about ADRs to get help and support in managing them. 
 
Medication management  
 
To better manage their treatment regimen most patients had developed different 
strategies making the daily medication-taking easier and suitable for their schedules. 
Some of the used tools were a weekly dosette, a phone reminder, a certain routine or 
carrying medications with them.  Couple patients who were on nilotinib found it often 
challenging to incorporate the medicine-taking in to their daily schedule, because the 
medication has to be taken into an empty stomach without a meal. This can be a factor 
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affecting the quality of life, especially if it is present most of the days, like one patient 
stated: “It is not a big problem, but still always a little bit in your mind.” The patients 
who were on imatinib faced sometimes the same issues, but in their case the challenge 
was to time the imatinib-taking with meals to avoid ADRs getting worse. 
 
Considering that the majority of the patients had sometimes forgotten to take their 
medication but only a third reported using any compliance aids such as a dosette or a 
phone reminder, more patients could benefit the use of compliance aids. HCPs can have 
an important role in helping their patients to better adhere to the treatment, for example 
providing information about the available compliance aids.  
 
11.2.3 Social support 
 
The association between social support and adherence is inconsistent in previous 
studies. Efficace et al. (2012) found that better social support was associated with better 
adherence, while Kapoor et al. (2012) suggested in their study that there was no 
association between social support and adherence. Nevertheless, social support is 
important to patients in many ways. It can provide mental and practical help for the 
patients to deal with the challenges they might be facing with their disease.  
Nonadherent patients had a good social support network that consisted of the spouses, 
family members, friends, co-workers and online forums of other CML patients. Patients 
reported having received both practical and emotional support.  
 
Patient network group is another form of support, providing peer support and 
information. Nonadherent patients in this study had not been actively involved in the 
patient network. However, getting involved would provide patients with peer support 
from other people living with the same disease. Sharing experiences with other patients 
could help patients to deal with difficult moments and how to overcome them. Patients 
might need more information about the network and how to get involved so that it 
would be easier to participate and this way more patients could benefit from the 
organization. 
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11.2.4 HCP related factors 
 
In assessing how treatment was provided and organized by hospitals, diagnosis, support 
from HCPs and a follow-up system was included and information was obtained from 
the theme interviews. Over all, patients were very satisfied for the care received, the 
quality of the care and the knowledge of physicians and HCPs. 
 
The emphasis on the term adherence is on the agreement between a patient and a 
physician (The World Health Organization, 2003) and this would be important to keep 
in mind when starting the new treatment. A good, long-term relationship between a 
physician and a patient could be an important factor affecting patient’s attitude towards 
disease and adherence to the treatment. In this, a good communication and trust 
between a patient and a physician can play an important role. Patients whose physicians 
changed frequently had no continuous support or someone to turn to in case of urgent 
concerns. The findings in this study suggest that the support from the physician was 
very important for the patients. Two thirds of the patients had usually the same doctor 
and this was something that patients valued.  Both, informational and emotional support 
from the physician and HCPs had positive impact on patients.   
 
Many patients did not know much about CML prior to diagnosis and that is why 
learning about it for the first time was frightening and a big shock. Patient thought it 
was important for doctor to highlight the fact that even though CML is a serious 
disease, there are good medications available and it is treatable, being rather a chronic 
condition. Six patients received the diagnosis over the phone, which is not ideal when it 
is about a serious disease and this might not provide a good basis for dealing with CML. 
Patients had lots of questions and concerns about CML especially right after receiving 
the diagnosis and the support and interaction between physicians and nurses was 
important. However, for the patients who received diagnosis over the phone, there was 
no chance to ask questions or express concerns that came first in mind.  
 
Over half of the patients mentioned that they received enough information about CML 
and its treatment while six patients would have needed more information. It made 
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patients feeling better once they got a better understanding about the nature of the 
disease.  When starting the treatment, it would be important for a physician to discuss 
with the patient regarding the treatment options, their benefits and possible ADRs. One 
patient mentioned how it would have been good if doctor warned about possible ADRs 
in advance. In a previous study it has been shown to be very important for patients 
dealing with ADRs caused by oral chemotherapy, that oncologist provides information 
about major ADRs and how to manage them in case they occur (Regnier Denois et al. 
2011). In the same study, doctors who did not want to warn about ADRs in advanced 
justified this by stating that they do not want to scare patients about ADRs because it 
could result in patients not wanting to start the treatment. However, if the patient has 
already had a discussion about possible ADRs with the physician it might be easier for 
the patient to bring it up later on. Doctors should also explain about the importance of 
adherence in the treatment outcome and to listen about patient’s questions and concerns 
about the treatment. Some patients might need more time to process the received 
information, as too much information at once can be overwhelming. Also, if all the 
information is given at once, a patient may not be able to remember all of it.  
 
Over half of the patients had actively searched additional information mainly from 
Internet about CML, its treatment and other CML patients’ experiences. Desire for 
information is good and indicates that patients are motivated to learn more about their 
disease. Because Internet is full of all kind of information from different sources, 
patients might need guidance where and how to find reliable and latest science based 
information. It is important that patient has a good understanding about the disease, its 
treatment and the importance of adequate adherence. This can motivate patients to take 
more responsibility about managing their treatment. Physicians should educate their 
patients during follow-up appointments and remind them about important treatment 
related factors.  
 
Having the same physician can provide patient with long-term support but also help a 
doctor to get to know a patient well. This is important because it is easier to 
continuously assess adherence if a physician knows a patient well, as adherence may 
change over time. Eliasson et al (2011) found in their study that at the beginning of the 
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treatment unintentional nonadherence was more common and later on intentional 
adherence became more common.  
 
In addition to physicians, other HCPs such as nurses, social workers, psychologists and 
pharmacists can support and help patients to succeed with their treatment. However, 
many patients were not informed about the services provided by hospitals or could not 
get the hold of the psychologist despite several attempts. This is unfortunate as some of 
the patients mentioned that they would have benefit the additional support. In 
identifying nonadherence, pharmacists could easily spot any inconsistencies in refilling 
prescriptions. In such case, would be good if a pharmacist brought it up and asked about 
the possible issues patient might have been facing in managing their treatment regimen. 
Pharmacists could then provide support and tips how to make medication management 
easier or refer to a treating physician. 
 
11.3 Further research and utilization of the results 
 
The study is part of the larger study and consists of large amount of patient data that 
could be used in further studies. For example the theme-interviews were analyzed only 
from the nonadherent patients, which is a small portion of the total patient data. Would 
be interesting to analyze the theme-interviews of patients who were classified as high 
and medium adherent. Interviews consisted of interesting thoughts and experiences of 
patients about their daily life and how it was affected by CML and the treatment 
regimen along with the ADRs. Would be interesting to study how better adherent 
patients deal with ADRs and medication-management related issues and if there are any 
differences in this between nonadherent and better adherent patients. This could further 
help in understanding the factors that lead to nonadherent or adherent behaviour. 
 
Because CML is a chronic, life long disease, it is important to pay attention to the 
obstacles that patients may face with their treatment regiment such as ADRs and 
medication management. The findings from this thesis can be utilized by all HCPs who 
are working with CML patients in hospitals, occupational health clinics, health stations 
and pharmacies. It will hopefully help HCPs to understand the challenges of TKI 
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treatment from the patient’s perspective. This is important in providing comprehensive 
care for the patients and helping to improve their quality of life.  
  
 
12 CONCLUSION 
 
1.  Of 86 patients 18 (21%) were considered having poor adherence and 10 (23%) 
high adherence to their TKI treatment, based on the MMAS-8 adherence questionnaire. 
 
2. Patient sociodemographic characteristics or experienced ADRs did not predict 
adherence. There was a significant association between high adherence and more 
concomitant medications and more comorbidities.  
 
3. All the nonadherent patients reported unintentional adherence and two-thirds 
intentional adherence. Forgetting was the most common reason for unintentional 
adherence. Common reasons for intentional adherence were ARDs, travelling, while 
being on holidays or when visiting. 
 
4. Patients were very satisfied with their physicians, the treatment received and the 
quality of care. The majority of the patients were happy for the support from the 
physician and other HCPs and it was felt important especially at the beginning. 
 
5. Patients had different strategies for managing medication-taking, such as having 
daily routines or using a dosette. Many patients had difficulties in incorporating 
medication-taking into the daily schedule, when the medication had to be taken with 
food or to an empty stomach. 
 
6.  Reasons for nonadherence are complex. A patient should be faced as an 
individual and identify the problems or issues he/she is facing so that they could be 
better addressed. 
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 APPENDIX 1. Morisky Medication Adherence Scale (MMAS-8-Item) 
©Morisky Medication Adherence Scale (MMAS-8-Item). 
You indicated that you are taking medication(s) for your chronic myelogenous leukemia. 
Individuals have identified several issues regarding their medication-taking behavior and 
we are interested in your experiences. There is no right or wrong answer. Please answer 
each question based on your personal experience with your chronic myelogenous leukemia 
medication. 
(Please check your response below) 
 No=1 Yes=0 
1. Do you sometimes forget to take your chronic myelogenous leukemia 
medication(s)? 
  
2. People sometimes miss taking their medications for reasons other than 
forgetting. Thinking over the past two weeks, were there any days when you 
did not take your chronic myelogenous leukemia medication(s)? 
  
3. Have you ever cut back or stopped taking your medication(s) without telling 
your doctor, because you felt worse when you took it? 
  
4. When you travel or leave home, do you sometimes forget to bring along 
your chronic myelogenous leukemia medication(s)? 
  
5. Did you take your chronic myelogenous leukemia medication(s) yesterday?   
6. When you feel like your chronic myelogenous leukemia is under control, do 
you sometimes stop taking your medication(s)? 
  
7. Taking medication(s) every day is a real inconvenience for some people. Do 
you ever feel hassled about sticking to your chronic myelogenous leukemia 
treatment plan? 
  
8. How often do you have difficulty remembering to take all your medication(s)? 
(Please circle the correct number)  
 
Never/Rarely........................................... 4 
Once in a while....................................... 3  
Sometimes.............................................. 2  
Usually................................................... 1  
All the time............................................ 0 
 
 
 APPENDIX 2.  
 
Questions to evaluate CML patient’s knowledge of the disease and TKI treatment. 
 
 
Question 1. What is CML? 
 
Question 2. What has happened in your body (the cause of CML)? 
 
Question 3. What does the TKI medication do in your body (how does the  
  medication work)? 
 
Question 4. What kind of side effects might the medication cause? 
 
Question 5. (Have you talked with your doctor?) What happens if you skip a  
  dose/stop taking your TKI medication? 
 
 
Each question has a value of 1 point. The total score will range from 0-5.  
 
 
 
 
 
 
 
 
 
 
 
